Anders Sönnerborg

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Professor i klinisk virologi vid Karolinska Institutet sedan 2012. Chef för avdelningen för infektionssjukdomar och hud vid institutionen för medicin, Huddinge.

Artiklar

Article: EUROSURVEILLANCE. 2024;29(42):2400058
Sweden surpasses the UNAIDS 95-95-95 target: estimating HIV-1 incidence, 2003 to 2022
Lundgren E; Locke M; Romero-Severson E; Dimitrijevic M; Axelsson M; Andersson E; Carlander C; Brannstroem J; Norrgren H; Mansson F; Elvstam O; Gisslen M; Fohlin L; Sonnerborg A; Albert J; Leitner T
Article: CURRENT OPINION IN HIV AND AIDS. 2024;19(5):261-267
Elite controllers microbiome: unraveling the mystery of association and causation
Bai X; Sonnerborg A; Nowak P
Article: CLINICAL INFECTIOUS DISEASES. 2024;:ciae406
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort Consortium
Rupasinghe D; Bansi-Matharu L; Law M; Zangerle R; Rauch A; Tarr PE; Greenberg L; Neesgaard B; Jaschinski N; De Wit S; Wit F; d'Arminio Monforte A; Fontas E; Castagna A; Stecher M; Florence E; Begovac J; Mussini C; Sonnerborg A; Abutidze A; Groh A; Vannappagari V; Cohen C; Young L; Hosein S; Ryom L; Petoumenos K
Article: INFECTIOUS DISEASES. 2024;56(8):657-668
Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024
Naver L; Albert J; Carlander C; Gisslen M; Pettersson K; Soeria-Atmadja S; Sonnerborg A; Westling K; Yilmaz A; Pettersson K
Article: SCIENTIFIC REPORTS. 2024;14(1):17820
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV
Narayanan A; Kieri O; Vesterbacka J; Manoharan L; Chen P; Ghorbani M; Ljunggren H-G; Chen MS; Aleman S; Soennerborg A; Ray S; Nowak P
Article: BIOINFORMATICS. 2024;40(6):btae327
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1
Di Teodoro G; Pirkl M; Incardona F; Vicenti I; Sonnerborg A; Kaiser R; Palagi L; Zazzi M; Lengauer T
Article: AIDS. 2024;38(4):497-508
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes
Mocroft A; Pelchen-Matthews A; Hoy J; Llibre JM; Neesgaard B; Jaschinski N; Domingo P; Rasmussen LD; Gunthard HF; Surial B; Ollinger A; Knappik M; de Wit S; Wit F; Mussini C; Vehreschild J; Monforte AD; Sonnerborg A; Castagna A; Anne AV; Vannappagari V; Cohen C; Greaves W; Wasmuth JC; Spagnuolo V; Ryom L
Article: THE LANCET REGIONAL HEALTH. EUROPE. 2024;38:100855
In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project
Hedberg P; Parczewski M; Serwin K; Marchetti G; Bai F; Jensen B-EO; Pereira JPV; Drobniewski F; Reschreiter H; Naumovas D; Ceccherini-Silberstein F; Quintanares GHR; Mwau M; Toscano C; Koenig F; Pfeifer N; Zazzi M; Fanti I; Incardona F; Cozzi-Lepri A; Soennerborg A; Naucler P
Article: HIV MEDICINE. 2024;25(1):107-116
Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression
Elen S; Bjorkman P; Zazzi M; Bohm M; Bernal E; Sonnerborg A; Elvstam O
Article: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2024;14:1334126
Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1
Giammarino F; Sonnerborg A; Cena-Diez R
Article: NPJ BIOFILMS AND MICROBIOMES. 2023;9(1):104
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren H-G; Buggert M; Manoharan L; Chen MS; Aleman S; Sonnerborg A; Nowak P
Article: EUROSURVEILLANCE. 2023;28(48):2300224
The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
Waernberg AW; Braennstroem J; Elvstam O; Gisslen M; Mansson F; Soennerborg A; Klundert MAAVD
Article: BMC INFECTIOUS DISEASES. 2023;23(1):690
EuCARE-hospitalised study protocol: a cohort study of patients hospitalised with COVID-19 in the EuCARE project
Hedberg P; Varisco B; Bai F; Sonnerborg A; Naucler P; Pfeifer N; Cozzi-Lepri A; Ceccherini-Silberstein F; Naumovas D; Drobniewski F; Jensen B-EO; Toscano C; Parczewski M; Quintanares GHR; Mwau M; Pinto JA; Incardona F; Mommo C; Marchetti G
Article: CLINICAL INFECTIOUS DISEASES. 2023;77(4):593-605
Plasma Human Immunodeficiency Virus 1 RNA and CD4⁺ T-Cell Counts are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study
Alvarez H; Mocroft A; Ryom L; Neesgaard B; Edwards S; Svedhem V; Guenthard HF; Zangerle R; Smith C; Castagna A; d'Arminio Monforte A; Wit F; Stecher M; Lehman C; Mussini C; Fontas E; Gonzalez E; Wasmuth J-C; Soennerborg A; De Wit S; Chkhartishvili N; Stephan C; Petoumenos K; Jaschinski N; Vannappagari V; Gallant J; Young L; Volny Anne A; Greenberg L; Martin-Iguacel R; Poveda E; Llibre JM
Article: JOURNAL OF BIOMEDICAL INFORMATICS. 2023;144:104436
Generating synthetic clinical data that capture class imbalanced distributions with generative adversarial networks: Example using antiretroviral therapy for HIV
Kuo NI-H; Garcia F; Soennerborg A; Boehm M; Kaiser R; Zazzi M; Polizzotto M; Jorm L; Barbieri S
Article: AIDS. 2023;37(7):1023-1033
Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment
Svensson Akusjarvi S; Krishnan S; Ambikan AT; Mikaeloff F; Munusamy Ponnan S; Vesterbacka J; Lourda M; Nowak P; Sonnerborg A; Neogi U
Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2023;61(5):106792
Naturally occurring dipeptide from elite controllers with dual anti-HIV-1 mechanism
Cena-Diez R; Narayanan A; Ray S; van de Klundert M; Rodriguez JE; Nilvebrant J; Nygren P-A; Vegvari A; van Domselaar R; Sonnerborg A
Article: TROPICAL MEDICINE AND INFECTIOUS DISEASE. 2023;8(5):243
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)
Rossetti B; Incardona F; Di Teodoro G; Mommo C; Saladini F; Kaiser R; Sonnerborg A; Lengauer T; Zazzi M
Article: JOURNAL OF INTERNAL MEDICINE. 2023;293(4):445-456
Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV
Ripamonti E; Eden A; Nilsson S; Sonnerborg A; Zetterberg H; Gisslen M
Article: BMJ OPEN. 2023;13(3):e069688
Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden
Carlander C; Brannstrom J; Mansson F; Elvstam O; Albinsson P; Blom S; Mattsson L; Hovmoller S; Norrgren H; Mellgren A; Svedhem V; Gisslen M; Sonnerborg A
Article: AIDS. 2023;37(3):467-475
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV
Jaschinski N; Greenberg L; Neesgaard B; Miro JM; Grabmeier-Pfistershammer K; Wandeler G; Smith C; De Wit S; Wit F; Pelchen-Matthews A; Mussini C; Castagna A; Pradier C; Monforte AD; Vehreschild J; Sonnerborg A; Anne AV; Carr A; Bansi-Matharu L; Lundgren J; Garges H; Rogatto F; Zangerle R; Gunthard HF; Rasmussen LD; Nescoi C; Van der Valk M; Menozzi M; Muccini C; Mocroft A; Peters L; Ryom L
Article: CLINICAL INFECTIOUS DISEASES. 2023;76(1):25-31
Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
Elvstam O; Malmborn K; Elen S; Marrone G; Garcia F; Zazzi M; Sonnerborg A; Boehm M; Seguin-Devaux C; Bjorkman P
Article: JOURNAL OF MEDICAL VIROLOGY. 2023;95(1):e28389
Analysis of mutational history of multidrug-resistant genotypes with a mutagenetic tree model
Pirkl M; Buech J; Devaux C; Boehm M; Sonnerborg A; Incardona F; Abecasis A; Vandamme A-M; Zazzi M; Kaiser R; Lengauer T
Article: PLOS ONE. 2023;18(12):e0295838
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: SCIENTIFIC DATA. 2022;9(1):693
The Health Gym: synthetic health-related datasets for the development of reinforcement learning algorithms
Kuo NI-H; Polizzotto MN; Finfer S; Garcia F; Sonnerborg A; Zazzi M; Boehm M; Kaiser R; Jorm L; Barbieri S
Article: ADVANCED SCIENCE. 2022;9(32):e2203898
Synthetic Mucin Gels with Self-Healing Properties Augment Lubricity and Inhibit HIV-1 and HSV-2 Transmission
Kretschmer M; Cena-Diez R; Butnarasu C; Silveira V; Dobryden I; Visentin S; Berglund P; Sonnerborg A; Lieleg O; Crouzier T; Yan H
Article: BIOMEDICINES. 2022;10(10):2593
Continued Complexity of Mutations in Omicron Sublineages
Spratt AN; Kannan SR; Sharma K; Sachdev S; Kandasamy SL; Sonnerborg A; Lorson CL; Singh K
Article: VIRUSES. 2022;14(10):2099
Molecular Epidemiology of HIV-1 in Eastern Europe and Russia
van de Klundert MAA; Antonova A; Di Teodoro G; Diez RC; Chkhartishvili N; Heger E; Kuznetsova A; Lebedev A; Narayanan A; Ozhmegova E; Pronin A; Shemshura A; Tumanov A; Pfeifer N; Kaiser R; Saladini F; Zazzi M; Incardona F; Bobkova M; Sonnerborg A
Article: LIFE SCIENCE ALLIANCE. 2022;5(9):e202201405
Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection
Ambikan AT; Svensson-Akusjarvi S; Krishnan S; Sperk M; Nowak P; Vesterbacka J; Sonnerborg A; Benfeitas R; Neogi U
Article: CELL SYSTEMS. 2022;13(8):665-681.e4
Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity
Ambikan AT; Yang H; Krishnan S; Akusjarvi SS; Gupta S; Lourda M; Sperk M; Arif M; Zhang C; Nordqvist H; Ponnan SM; Sonnerborg A; Treutiger CJ; O'Mahony L; Mardinoglu A; Benfeitas R; Neogi U
Article: HIV MEDICINE. 2022;23(7):774-789
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sonnerborg A; Zazzi M
Article: THE LANCET HIV. 2022;9(7):e474-e485
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
Neesgaard B; Greenberg L; Miro JM; Grabmeier-Pfistershammer K; Wandeler G; Smith C; De Wit S; Wit F; Pelchen-Matthews A; Mussini C; Castagna A; Pradier C; Monforte AD; Vehreschild JJ; Sonnerborg A; Anne AV; Carr A; Bansi-Matharu L; Lundgren JD; Garges H; Rogatto F; Zangerle R; Gunthard HF; Rasmussen LD; Necsoi C; van der Valk M; Menozzi M; Muccini C; Peters L; Mocroft A; Ryom L
Article: PLOS PATHOGENS. 2022;18(6):e1010555
T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin
Lindqvist B; Jutte BB; Love L; Assi W; Roux J; Sonnerborg A; Tezil T; Verdin E; Svensson JP
Article: INFECTIOUS DISEASES AND THERAPY. 2022;11(3):1103-1116
Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile
Cena-Diez R; Singh K; Spetz A-L; Sonnerborg A
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(10):5534
Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions
Kannan SR; Spratt AN; Sharma K; Goyal R; Sonnerborg A; Apparsundaram S; Lorson CL; Byrareddy SN; Singh K
Article: PATHOGENS. 2022;11(5):546
Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
Rhee S-Y; Boehm M; Tarasova O; Di Teodoro G; Abecasis AB; Sonnerborg A; Bailey AJ; Kireev D; Zazzi M; Shafer RW
Article: BIOMEDICINES. 2022;10(5):982
Characterization of the Upper Respiratory Bacterial Microbiome in Critically Ill COVID-19 Patients
Bai X; Narayanan A; Skagerberg M; Cena-Diez R; Giske CG; Stralin K; Sonnerborg A
Article: COMMUNICATIONS BIOLOGY. 2022;5(1):357
Peripheral blood CD4⁺CCR6⁺ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals
Svensson Akusjarvi S; Krishnan S; Jutte BB; Ambikan AT; Gupta S; Rodriguez JE; Vegvari A; Sperk M; Nowak P; Vesterbacka J; Svensson JP; Sonnerborg A; Neogi U
Article: OPEN FORUM INFECTIOUS DISEASES. 2022;9(3):ofac029
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
Greenberg L; Ryom L; Neesgaard B; Miro JM; Rasmussen LD; Zangerle R; Grabmeier-Pfistershammer K; Gunthard HF; Kusejko K; Smith C; Mussini C; Menozzi M; Wit F; Van der Valk M; Monforte AD; De Wit S; Necsoi C; Pelchen-Matthews A; Lundgren J; Peters L; Castagna A; Muccini C; Vehreschild JJ; Pradier C; Riera AB; Sonnerborg A; Petoumenos K; Garges H; Rogatto F; Dedes N; Bansi-Matharu L; Mocroft A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38(2):135-142
Incidence, Treatment, and Outcome of HIV-Associated Hematologic Malignancies in People Living with HIV in Sweden
Kieri O; Marrone G; Sonnerborg A; Nowak P
Article: ISCIENCE. 2022;25(1):103607
Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling
Akusjarvi SS; Ambikan AT; Krishnan S; Gupta S; Sperk M; Vegvari A; Mikaeloff F; Healy K; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:1067767
Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors
Milao JF; Love L; Gourgi G; Derhaschnig L; Svensson JP; Soennerborg A; van Domselaar R
Article: CLINICAL INFECTIOUS DISEASES. 2021;73(7):e2323-e2333
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus
Greenberg L; Ryom L; Neesgaard B; Wandeler G; Staub T; Gisinger M; Skoll M; Gunthard HF; Scherrer A; Mussini C; Smith C; Johnson M; De Wit S; Necsoi C; Pradier C; Wit F; Lehmann C; Monforte AD; Miro JM; Castagna A; Spagnuolo V; Sonnerborg A; Law M; Hutchinson J; Chkhartishvili N; Bolokadze N; Wasmuth J-C; Stephan C; Vannappagari V; Rogatto F; Llibre JM; Duvivier C; Hoy J; Bloch M; Bucher HC; Calmy A; Anne AV; Pelchen-Matthews A; Lundgren JD; Peters L; Bansi-Matharu L; Mocroft A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2021;118(40):e2109123118
High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of in COVID-19
Lourda M; Dzidic M; Hertwig L; Bergsten H; Medina LMP; Sinha I; Kvedaraite E; Chen P; Muvva JR; Gorin J-B; Cornillet M; Emgard J; Moll K; Garcia M; Maleki KT; Klingstrom J; Michaelsson J; Flodstrom-Tullberg M; Brighenti S; Buggert M; Mjosberg J; Malmberg K-J; Sandberg JK; Henter J-I; Folkesson E; Gredmark-Russ S; Sonnerborg A; Eriksson LI; Rooyackers O; Aleman S; Stralin K; Ljunggren H-G; Bjorkstrom NK; Svensson M; Ponzetta A; Norrby-Teglund A; Chambers BJ
Article: JOURNAL OF VIROLOGY. 2021;95(18):e0047921-10.1128/jvi.00421
Fecal Metabolome Signature in the HIV-1 Elite Control Phenotype: Enrichment of Dipeptides Acts as an HIV-1 Antagonist but a Prevotella Agonist
Sperk M; Ambikan AT; Ray S; Singh K; Mikaeloff F; Diez RC; Narayanan A; Vesterbacka J; Nowak P; Sonnerborg A; Neogi U
Article: EUROSURVEILLANCE. 2021;26(33):2000161
Post-migration acquisition of HIV: Estimates from four European countries, 2007 to 2016
Yin Z; Brown AE; Rice BD; Marrone G; Sonnerborg A; Suligoi B; Sasse A; Van Beckhoven D; Noori T; Regine V; Delpech VC
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021;76(9):2394-2399
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study
Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sonnerborg A; Zazzi M
Article: CLINICAL INFECTIOUS DISEASES. 2021;72(12):2079-2086
All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study
Elvstam O; Marrone G; Medstrand P; Treutiger CJ; Sonnerborg A; Gisslen M; Bjorkman P
Article: ACS INFECTIOUS DISEASES. 2021;7(5):1104-1115
Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine
Ray S; Narayanan A; Giske CG; Neogi U; Sonnerborg A; Nowak P
Article: AIDS. 2021;35(6):869-882
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
Byonanebye DM; Polizzotto MN; Begovac J; Grabmeier-Pfistershammer K; Abela I; Castagna A; De Wit S; Mussini C; Vehreschild JJ; Monforte AD; Wit FWNM; Pradier C; Chkhartishvili N; Sonnerborg A; Hoy J; Lundgren J; Neesgaard B; Bansi-matharu L; Greenberg L; Llibre JM; Vannappagari V; Gallant J; Necsoi C; Cichon P; Reiss P; Aho I; Tsertsvadze T; Mennozzi M; Rauch A; Muccini C; Law M; Mocroft A; Ryom L; Petoumenos K
Article: HELIYON. 2021;7(5):e07134
Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death
Szekely L; Bozoky B; Bendek M; Ostad M; Lavignasse P; Haag L; Wu J; Jing X; Gupta S; Saccon E; Sonnerberg A; Cao Y; Bjornstedt M; Szakos A
Article: ISCIENCE. 2021;24(2):102111
Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status
Sperk M; Mikaeloff F; Svensson-Akusjarvi S; Krishnan S; Ponnan SM; Ambikan AT; Nowak P; Sonnerborg A; Neogi U
Article: AIDS. 2021;35(2):227-234
High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden
Andersson E; Ambikan A; Brannstrom J; Aralaguppe SG; Yilmaz A; Albert J; Neogi U; Sonnerborg A
Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication
Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjarvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlen G; Asghar M; Sallberg M; Vesterbacka J; Nowak P; Vegvari A; Sonnerborg A; Treutiger CJ; Neogi U
Article: FRONTIERS IN MICROBIOLOGY. 2021;12:667718
Whole-Genome Metagenomic Analysis of the Gut Microbiome in HIV-1-Infected Individuals on Antiretroviral Therapy
Bai X; Narayanan A; Nowak P; Ray S; Neogi U; Sonnerborg A
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:669347
Cytotoxic Lymphocytes Target HIV-1 Gag Through Granzyme M-Mediated Cleavage
Saccon E; Mikaeloff F; Ivern PF; Vegvari A; Sonnerborg A; Neogi U; van Domselaar R
Article: HIV MEDICINE. 2021;22(1):22-27
Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors
Borghetti A; Ciccullo A; Lombardi F; Baldin G; Belmonti S; Prosperi M; Incardona F; Heger E; Borghi V; Sonnerborg A; Zazzi M; De Luca A; Di Giambenedetto S
Article: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2021;19:3799-3809
Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants
Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sonnerborg A; Byrareddy SN; Singh K
Article: EMERGING MICROBES AND INFECTIONS. 2021;10(1):1919-1930
HIV-1 CRF07_BC transmission dynamics in China: two decades of national molecular surveillance
Ge Z; Feng Y; Zhang H; Rashid A; Zaongo SD; Li K; Yu Y; Lv B; Sun J; Liang Y; Xing H; Sonnerborg A; Ma P; Shao Y
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
Sandberg JT; Varnaite R; Christ W; Chen P; Muvva JR; Maleki KT; Garcia M; Dzidic M; Folkesson E; Skagerberg M; Ahlen G; Frelin L; Sallberg M; Eriksson LI; Rooyackers O; Sonnerborg A; Buggert M; Bjorkstrom NK; Aleman S; Stralin K; Klingstrom J; Ljunggren H-G; Blom K; Gredmark-Russ S
Article: CLINICAL INFECTIOUS DISEASES. 2020;71(11):2905-2916
Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?
Vourli G; Noori T; Pharris A; Porter K; Axelsson M; Begovac J; Cazein F; Costagliola D; Cowan S; Croxford S; Monforte AD; Delpech V; Diaz A; Girardi E; Gunsenheimer-Bartmeyer B; Hernando V; Leierer G; Lot F; Nunez O; Obel N; de Coul EO; Paraskeva D; Patrinos S; Reiss P; Schmid D; Sonnerborg A; Suligoi B; Supervie V; van Sighem A; Zangerle R; Touloumi G
Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2020;29(12):2662-2668
HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study
Carlander C; Lagheden C; Eklund C; Kleppe SN; Dzabic M; Wagner P; Yilmaz A; Elfgren K; Sonnerborg A; Sparen P; Dillner J
Article: LAKARTIDNINGEN. 2020;117:20180
[Future testing for SARS-CoV-2: not only more but smarter].
Andersson E; Sönnerborg A
Article: CELL. 2020;183(1):158-168.e14
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine T; Perez-Potti A; Rivera-Ballesteros O; Stralin K; Gorin J-B; Olsson A; Llewellyn-Lacey S; Kamal H; Bogdanovic G; Muschiol S; Wullimann DJ; Kammann T; Emgard J; Parrot T; Folkesson E; Rooyackers O; Eriksson LI; Henter J-I; Sonnerborg A; Allander T; Albert J; Nielsen M; Klingstrom J; Gredmark-Russ S; Bjorkstrom NK; Sandberg JK; Price DA; Ljunggren H-G; Aleman S; Buggert M
Article: MICROORGANISMS. 2020;8(8):E1164-1164
How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium
Neesgaard B; Mocroft A; Greenberg L; Larsen JF; Wandeler G; Zangerle R; Gunthard H; Smith C; De Wit S; Mussini C; Castagna A; Monforte AD; Vehreschild JJ; Wasmuth J-C; Pradier C; Chkhartishvili N; Wit FWNM; Law M; Sonnerborg A; Bruguera A; Stephan C; Vannappagari V; Haubrich R; Kirk O; Podlekareva D; Kowalska J; Raben D; Rockstroh J; Peters L; Parades R; Grabmeier-Pfistershammer K; Scherrer A; Johnson M; Necsoi C; Borghi V; Muccini C; Tserstvadze T; Petoumenos K; Volny-Anne A; Lundgren J; Ryom L
Article: LAKARTIDNINGEN. 2020;117:F3UA
[Bats and humans].
Sönnerborg A
Article: PATHOGENS. 2020;9(5):E320-320
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
Neogi U; Hill KJ; Ambikan AT; Heng X; Quinn TP; Byrareddy SN; Soennerborg A; Sarafianos SG; Singh K
Article: VIRUSES. 2020;12(4):E475-475
HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia
Schloesser M; Kartashev VV; Mikkola VH; Shemshura A; Saukhat S; Kolpakov D; Suladze A; Tverdokhlebova T; Hutt K; Heger E; Knops E; Boehm M; Di Cristanziano V; Kaiser R; Sonnerborg A; Zazzi M; Bobkova M; Sierra S
Article: LAKARTIDNINGEN. 2020;117:F3HW
Covid-19 – uppdatering om klinisk bild och behandling.
Glans H; Sönnerborg A; Aleman S
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020;17(5):E1809-1809
Delayed Treatment for People Living with HIV in China, 2004-2016: An Analysis of An Observational Cohort
Xu J; Soennerborg A; Gao L; Wang P; Bouey JZH; Cheng F
Article: PLOS ONE. 2020;15(12):e0243625
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Gunthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth J-C; Sonnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L
Article: PLOS PATHOGENS. 2020;16(1):e1008264
Chromatin maturation of the HIV-1 provirus in primary resting CD4⁺ T cells
Lindqvist B; Akusjarvi SS; Sonnerborg A; Dimitriou M; Svensson JP
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2020;9(12):e1224
Innate lymphoid cell composition associates with COVID-19 disease severity
Garcia M; Kokkinou E; Carrasco Garcia A; Parrot T; Palma Medina LM; Maleki KT; Christ W; Varnaite R; Filipovic I; Ljunggren H-G; Bjorkstrom NK; Folkesson E; Rooyackers O; Eriksson LI; Sonnerborg A; Aleman S; Stralin K; Gredmark-Russ S; Klingstrom J; Mjosberg J
Article: AIDS. 2019;33(13):2013-2024
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe
Neesgaard B; Pelchen-Matthews A; Ryom L; Florence E; Peters L; Roen A; Svedhem V; Clarke A; Benfield T; Mitsura V; Moreno S; Beniowski M; Begovac J; Matulionyte R; Trofimova T; Elbirt D; Kundro M; Vullo V; Behrens G; Staub T; Ragone L; Vannappagari V; Lundgren J; Mocroft A
Article: AIDS. 2019;33(11):1757-1763
HIV elite control is associated with reduced TRAILshort expression
Paim AC; Cummins NW; Natesampillai S; Garcia-Rivera E; Kogan N; Neogi U; Sonnerborg A; Sperk M; Bren GD; Deeks S; Polley E; Badley AD
Article: VIRUSES. 2019;11(9):E806-806
MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors
Aralaguppe SG; Ambikan AT; Ashokkumar M; Kumar MM; Hanna LE; Amogne W; Sonnerborg A; Neogi U
Article: STATISTICAL METHODS IN MEDICAL RESEARCH. 2019;28(7):1979-1997
Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data.
Pantazis N; Thomadakis C; Del Amo J; Alvarez-Del Arco D; Burns FM; Fakoya I; Touloumi G
Article: BMC INFECTIOUS DISEASES. 2019;19(1):569
A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort
Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Marrone G; Grossmann S; Neogi U; Tegbaru B; Sonnerborg A
Article: STATISTICS IN MEDICINE. 2019;38(10):1891-1902
Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models
Santacatterina M; Garcia-Pareja C; Bellocco R; Soennerborg A; Ekstrom AM; Bottai M
Article: JOURNAL OF INFECTION. 2019;78(5):402-408
Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics
Sarfo FS; Castelnuovo B; Fanti I; Feldt T; Incardona F; Kaiser R; Lwanga I; Marrone G; Sonnerborg A; Tufa TB; Zazzi M; De Luca A
Article: JOURNAL OF VIROLOGY. 2019;93(9):e00077-e00019
HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness
van Domselaar R; Njenda DT; Rao R; Sonnerborg A; Singh K; Neogi U
Article: LAB ON A CHIP. 2019;19(9):1657-1664
Microfluidic centrifugation assisted precipitation based DNA quantification
Banerjee I; Aralaguppe SG; Lapins N; Zhang W; Kazemzadeh A; Sonnerborg A; Neogi U; Russom A
Article: EUROSURVEILLANCE. 2019;24(14):30-37
Challenges in modelling the proportion of undiagnosed HIV infections in Sweden
Andersson E; Nakagawa F; van Sighem A; Axelsson M; Phillips AN; Sonnerborg A; Alber J
Article: HIV MEDICINE. 2019;20(4):264-273
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA
Amele S; Peters L; Sluzhynska M; Yakovlev A; Scherrer A; Domingo P; Gerstoft J; Viard JP; Gisinger M; Flisiak R; Bhaghani S; Ristola M; Leen C; Jablonowska E; Wandeler G; Stellbrink H; Falconer K; Monforte AD; Horban A; Rockstroh JK; Lundgren JD; Mocroft A; Losso M; Kundro M; Ramos Mejia JM; Schmied B; Zangerle R; Karpov I; Vassilenko A; Mitsura VM; Paduto D; Clumeck N; De Wit S; Delforge M; Florence E; Vandekerckhove L; Hadziosmanovic V; Begovac J; Machala L; Jilich D; Sedlacek D; Kronborg G; Benfield T; Gerstoft J; Katzenstein T; Pedersen C; Johansen IS; Ostergaard L; Wiese L; Moller NF; Nielsen LN; Zilmer K; Smidt J; Ristola M; Aho I; Viard J-P; Girard P-M; Pradier C; Fontas E; Duvivier C; Rockstroh J; Behrens G; Degen O; Stellbrink HJ; Stefan C; Bogner J; Fatkenheuer G; Chkhartishvili N; Gargalianos P; Xylomenos G; Armenis K; Sambatakou H; Szlavik J; Gottfredsson M; Mulcahy F; Yust I; Turner D; Burke M; Shahar E; Hassoun G; Elinav H; Haouzi M; Elbirt D; Sthoeger ZM; Monforte AD; Esposito R; Mazeu I; Mussini C; Mazzotta F; Gabbuti A; Vullo V; Lichtner M; Zaccarelli M; Antinori A; Acinapura R; Plazzi M; Lazzarin A; Castagna A; Gianotti N; Galli M; Ridolfo A; Rozentale B; Uzdaviniene V; Matulionyte R; Staub T; Hemmer R; Reiss P; Reikvam DH; Maeland A; Bruun J; Knysz B; Gasiorowski J; Inglot M; Bakowska E; Flisiak R; Grzeszczuk A; Parczewski M; Maciejewska K; Aksak-Was B; Beniowski M; Mularska E; Smiatacz T; Gensing M; Jablonowska E; Kamerys J; Wojcik K; Mozer-Lisewska I; Caldeira L; Mansinho K; Maltez F; Radoi R; Oprea C; Oprea C; Panteleev A; Panteleev O; Yakovlev A; Trofimora T; Khromova I; Kuzovatova E; Borodulina E; Vdoushkina E; Jevtovic D; Tomazic J; Miro JM; Laguno M; Martinez E; Garcia F; Blanco JL; Martinez-Rebollar M; Mallolas J; Moreno S; Rodriguez JM; Clotet B; Jou A; Paredes R; Tural C; Puig J; Bravo I; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Laporte JM; Falconer K; Thalme A; Sonnerborg A; Treutiger CJ; Flamholc L; Scherrer A; Weber R; Cavassini M; Calmy A; Furrer H; Battegay M; Schmid P; Kuznetsova A; Kyselyova G; Sluzhynska M; Gazzard B; Johnson AM; Simons E; Edwards S; Phillips A; Johnson MA; Mocroft A; Orkin C; Weber J; Scullard G; Clarke A; Leen C; Lundgren J; Rockstroh J; Rasmussen LD; Wandeler G; Oprea C; Kowalska JD; Miro J; Guaraldi G; Rockstroh J; Kirk O; Kirk O; Peters L; Bojesen A; Raben D; Kristensen D; Laut K; Larsen JF; Podlekareva D; Nykjaer B; Mocroft A; Phillips A; Cozzi-Lepri A; Amele S; Elchen-Matthews AP
Article: AIDS. 2019;33(3):588-592
Strain-specific effect on biphasic DNA binding by HIV-1 integrase
Hill KJ; Rogers LC; Njenda DT; Burke DH; Sarafianos SG; Sonnerborg A; Neogi U; Singh K
Article: AIDS. 2019;33(2):315-326
The effect of primary drug resistance on CD4⁺ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy
Schultze A; Torti C; Cozzi-Lepri A; Vandamme A-M; Zazzi M; Sambatakou H; De Luca A; Geretti AM; Sonnerborg A; Ruiz L; Monno L; Di Giambenedetto S; Gori A; Lapadula G
Article: AIDS. 2019;33(2):327-337
Effect of incident hepatitis C infection on CD4⁺ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort
van Santen DK; van der Helm JJ; Touloumi G; Pantazis N; Muga R; Gunsenheimer-Bartmeyer B; Gill MJ; Sanders E; Kelleher A; Zangerle R; Porter K; Prins M; Geskus RB; Del Amo J; Meyer L; Bucher HC; Chene G; Hamouda O; Pillay D; Rosinska M; Sabin C; Olson A; Cartier A; Fradette L; Walker S; Babiker A; De Luca A; Fisher M; Kelleher T; Cooper D; Grey P; Finlayson R; Bloch M; Ramacciotti T; Gelgor L; Smith D; Lutsar I; Dabis F; Thiebaut R; Costagliola D; Guiguet M; Vanhems P; Chaix M-L; Ghosn J; Boufassa F; Meixenberger K; Bannert N; Antoniadou A; Chrysos G; Daikos GL; Katsarou O; Rezza G; Dorrucci M; Monforte AD; Schuitemaker H; Sannes M; Kran A-MB; Rosinska M; Tor J; de Olalla PG; Cayla J; Moreno S; Monge S; del Romero J; Perez-Hoyos S; Sonnerborg A; Gunthard H; Scherrer A; Malyuta R; Murphy G; Johnson A; Phillips A; Morrison C; Salata R; Mugerwa R; Chipato T; Price MA; Gilmour J; Kamali A; Karita E; Burns F; Giaquinto C; Grarup J; Kirk O; Bailey H; Anne AV; Panteleev A; Thorne C; Aboulker J-P; Albert J; Asandi S; De Wit S; Reiss P; Gatell J; Karpov I; Ledergerber B; Lundgren J; Moller C; Rakhmanova A; Rockstroh J; Sandhu M; Dedes N; Fenton K; Pizzuti D; Vitoria M; Faggion S; Frost R; Raben D; Schwimmer C; Scott M
Article: FRONTIERS IN MICROBIOLOGY. 2019;10:613
Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium
Vinken L; Fransen K; Cuypers L; Alexiev I; Balotta C; Debaisieux L; Seguin-Devaux C; Ribas SG; Gomes P; Incardona F; Kaiser R; Ruelle J; Sayan M; Paraschiv S; Paredes R; Peeters M; Sonnerborg A; Vancutsem E; Vandamme A-M; Van den Wijngaert S; Van Ranst M; Verhofstede C; Stadler T; Lemey P; Van Laethem K
Article: FRONTIERS IN MICROBIOLOGY. 2019;10:1227
GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds
Singh K; Gallazzi F; Hill KJ; Burke DH; Lange MJ; Quinn TP; Neogi U; Sonnerborg A
Article: PLOS ONE. 2019;14(8):e0220108
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study-2012-2015
Raben D; Sullivan AK; Mocroft A; Kutsyna G; Hadziosmanovic V; Vassilenko A; Chkhartisvili N; Mitsura V; Pedersen C; Anderson J; Begovac J; Dragsted UB; Bertisch B; Grzeszczuk A; Minton J; Necsoi VC; Kitchen M; Ajana F; Sokhan A; Comi L; Farazmand P; Pesut D; De Wit S; Maria Gate J; Gazzard B; Monforte AD; Rockstroh JK; Yazdanpanah Y; Champenois K; Jakobsen ML; Lundgren JD; Clumeck N; Gatell J; Gazzard B; Lundgren J; Monforte AD; Rockstroh J; Mocroft A; Yazdanpanah Y; Zangerle R; Kitchen M; Vassilenko A; Necsoi C; Genotte AF; Pedersen C; Redder L; Caby F; Bouvet E; Khuong MA; Caldato S; Morlat P; Coban D; Arvieux C; Cabie A; Chkhartishvili N; Gerdes S; Sambatakou H; Sthoeger ZM; Elbirt D; Comi L; Bini T; Celesia BM; Gussio M; Brinkman K; Grzeszczuk A; Rosca EC; Pesut D; Goenaga Sanchez MA; Estrada VP; Ortega Gonzalez E; Ocampo A; Masia M; Agusti C; Sonnerborg A; Vernazza P; Sullivan A; Rayment M; Rae C; Foxton M; Morris S; Palfreeman A; Calderwood J; Ong ELC; Mummery D; Kuznetsova A; Sullivan A; Champenois K; Raben D; Jakobsen ML; Hansen EW
Article: PLOS ONE. 2019;14(5):e0217048
The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx
Huik K; Soodla P; Pauskar M; Owen SM; Luo W; Murphy G; Jogeda E-L; Kallas E; Rajasaar H; Avi R; Masciotra S; Lutsar I; Del Amo J; Meyer L; Bucher HC; Chene G; Hamouda O; Pillay D; Prins M; Rosinska M; Sabin C; Touloumi G; Porter K; Olson A; Cartier A; Fradette L; Walker S; Babiker A; De Luca A; Fisher M; Muga R; Kelleher T; Cooper D; Grey P; Finlayson R; Bloch M; Ramacciotti T; Gelgor L; Smith D; Zangerle R; Gill J; Dabis F; Thiebaut R; Costagliola D; Guiguet M; Vanhems P; Chaix M-L; Ghosn J; Boufassa F; Meixenberger K; Bannert N; Bartmeyer B; Antoniadou A; Chrysos G; Daikos GL; Pantazis N; Katsarou O; Rezza G; Dorrucci M; Monforte AD; Geskus R; van der Helm J; Schuitemaker H; Sannes M; Dyrhol-Riise AM; Kran A-MB; Rosinska M; Tor J; de Olalla PG; Cayla J; del Amo J; Moreno S; Monge S; del Romero J; Perez-Hoyos S; Sonnerborg A; Guenthard H; Scherrer A; Malyuta R; Johnson A; Phillips A; Morrison C; Salata R; Mugerwa R; Chipato T; Price MA; Gilmour J; Kamali A; Karita E; Burns F; Giaquinto C; Grarup J; Kirk O; Bailey H; Anne AV; Panteleev A; Thorne C; Aboulker J-P; Albert J; Asandi S; De Wit S; Reiss P; Gatell J; Karpov I; Ledergerber B; Lundgren J; Moller C; Rakhma-nova A; Rockstroh J; Sandhu M; Dedes N; Fenton K; Pizzuti D; Vitoria M; Faggion S; Frost R; Raben D; Schwimmer C; Scott M
Article: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2018;21(11):e25200
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.
Panayidou K; Davies M-A; Anderegg N; Egger M; IeDEA, COHERE, PHACS and IMPAACT 219C Collaboratio
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2018;73(10):2721-2728
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes
Njenda DT; Aralaguppe SG; Singh K; Rao R; Sonnerborg A; Sarafianos SG; Neogi U
Article: CURRENT HIV RESEARCH. 2018;16(2):113-120
Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods
Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
Article: AIDS. 2018;32(11):1475-1484
Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia
Carlander C; Wagner P; van Beirs A; Yilmaz A; Elfgren K; Dillner J; Sonnerborg A; Sparen P
Article: SCIENTIFIC REPORTS. 2018;8(1):7556
Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing
Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Abdurahman S; Marrone G; Neogi U; Tegbaru B; Sonnerborg A
Article: HIV MEDICINE. 2018;19(5):324-338
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe
Santos JR; Cozzi-Lepri A; Phillips A; De Wit S; Pedersen C; Reiss P; Blaxhult A; Lazzarin A; Sluzhynska M; Orkin C; Duvivier C; Bogner J; Gargalianos-Kakolyris P; Schmid P; Hassoun G; Khromova I; Beniowski M; Hadziosmanovic V; Sedlacek D; Paredes R; Lundgren JD
Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2018;51(5):733-738
Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
Sorstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sonnerborg A; Gisslen M; Yilmaz A
Article: AIDS. 2018;32(7):877-884
Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden
Andersson E; Nordquist A; Esbjornsson J; Flamholc L; Gisslen M; Hejdeman B; Marrone G; Norrgren H; Svedhem V; Wendahl S; Albert J; Sonnerborg A
Article: HIV MEDICINE. 2018;19(4):252-260
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.
Roen A; Laut K; Pelchen-Matthews A; Borodulina E; Caldeira L; Clarke A; Clotet B; d'Arminio Monforte A; Fätkenheuer G; Gatell Artigas JM; Karpov I; Kuznetsova A; Kyselyova G; Mozer-Lisewska I; Mulcahy F; Ragone L; Scherrer A; Uzdaviniene V; Vandekerckhove L; Vannappagari V; Ostergaard L; Mocroft A; EuroSIDA study
Article: PLOS PATHOGENS. 2018;14(4):e1006973
Limited immune surveillance in lymphoid tissue by cytolytic CD4+T cells during health and HIV disease
Buggert M; Nguyen S; McLane LM; Steblyanko M; Anikeeva N; Paquin-Proulx D; Del Rio Estrada PM; Ablanedo-Terrazas Y; Noyan K; Reuter MA; Demers K; Sandberg JK; Eller MA; Streeck H; Jansson M; Nowak P; Sonnerborg A; Canaday DH; Naji A; Wherry EJ; Robb ML; Deeks SG; Reyes-Teran G; Sykulev Y; Karlsson AC; Betts MR
Article: CLINICAL INFECTIOUS DISEASES. 2018;66(6):893-903
Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs
Anderegg N; Panayidou K; Abo Y; Alejos B; Althoff KN; Anastos K; Antinori A; Balestre E; Becquet R; Castagna A; Castelnuovo B; Chene G; Coelho L; Collins IJ; Costagliola D; Crabtree-Ramirez B; Dabis F; Monforte AD; Davies M-A; De Wit S; Delpech V; De La Mata NL; Duda S; Freeman A; Gange SJ; Grabmeier-Pfistershammer K; Gunsenheimer-Bartmeyer B; Jiamsakul A; Kitahata MM; Law M; Manzardo C; McGowan C; Meyer L; Moore R; Mussini C; Nakigoz G; Nash D; Ng OT; Obel N; Pantazis N; Poda A; Raben D; Reiss P; Riggen L; Sabin C; Sinayobye JD; Sonnerborg A; Stoeckle M; Thorne C; Torti C; Twizere C; Wasmuth J-C; Wittkop L; Wools-Kaloustian K; Yotebieng M; Kirk O; Egger M
Article: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2018;21(3):e25083
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.
Hatleberg CI; Ryom L; El-Sadr W; Mocroft A; Reiss P; De Wit S; Dabis F; Pradier C; d'Arminio Monforte A; Kovari H; Law M; Lundgren JD; Sabin CA; Data Collection of Adverse Events of Anti-HIV drug
Article: AIDS. 2018;32(4):469-476
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes
Neogi U; Singh K; Aralaguppe SG; Rogers LC; Njenda DT; Sarafianos SG; Hejdeman B; Sonnerborg A
Article: HIV MEDICINE. 2018;19(2):102-117
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.
Cozzi-Lepri A; Zangerle R; Machala L; Zilmer K; Ristola M; Pradier C; Kirk O; Sambatakou H; Fätkenheuer G; Yust I; Schmid P; Gottfredsson M; Khromova I; Jilich D; Flisiak R; Smidt J; Rozentale B; Radoi R; Losso MH; Lundgren JD; Mocroft A; EuroSIDA Study Group
Article: HIV MEDICINE. 2018;19(2):90-101
The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.
Shepherd L; Borges ÁH; Harvey R; Bower M; Grulich A; Silverberg M; Weber J; Ristola M; Viard J-P; Bogner JR; Gargalianos-Kakolyris P; Mussini C; Mansinho K; Yust I; Paduta D; Jilich D; Smiatacz T; Radoi R; Tomazic J; Plomgaard P; Frikke-Schmidt R; Lundgren J; Mocroft A; EuroSIDA in EuroCOORD
Article: AIDS. 2018;32(2):161-169
Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort
Olson A; Bannert N; Soennerborg A; de Mendoza C; Price M; Zangerle R; Chaix M-L; Prins M; Kran A-MB; Gill J; Paraskevis D; Porter K
Article: PLOS ONE. 2018;13(7):e0200505
Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia
Telele NF; Kalu AW; Marrone G; Gebre-Selassie S; Fekade D; Tegbaru B; Sonnerborg A
Article: FRONTIERS IN IMMUNOLOGY. 2018;9:19
Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+T Cells
Noyan K; Son N; Betts MR; Sonnerborg A; Buggert M
Article: EBIOMEDICINE. 2018;27:40-50
Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers
Zhang W; Ambikan AT; Sperk M; van Domselaar R; Nowak P; Noyan K; Russom A; Sonnerborg A; Neogi U
Article: FRONTIERS IN MICROBIOLOGY. 2018;9:1754
Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
Rogers L; Obasa AE; Jacobs GB; Sarafianos SG; Sonnerborg A; Neogi U; Singh K
Article: FRONTIERS IN MICROBIOLOGY. 2018;9:2358
Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution
Zhang W; Akusjarvi SS; Sonnerborg A; Neogi U
Article: BIOINFORMATICS. 2017;33(24):3993-3995
PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context
Libin P; Eynden EV; Incardona F; Nowe A; Bezenchek A; Sonnerborg A; Vandamme A-M; Theys K; Baele G
Article: JOURNAL OF INFECTIOUS DISEASES. 2017;216(9):1063-1069
Evaluating the Impact of Functional Genetic Variation on HIV-1 Control
McLaren PJ; Pulit SL; Gurdasani D; Bartha I; Shea PR; Pomilla C; Gupta N; Gkrania-Klotsas E; Young EH; Bannert N; Del Amo J; Gill MJ; Gilmour J; Kellam P; Kelleher AD; Sonnerborg A; Zangerle R; Post FA; Fisher M; Haas DW; Walker BD; Porter K; Goldstein DB; Sandhu MS; de Bakker PIW; Fellay J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017;72(10):2869-2878
CD4 cell count response to first-line combination ART in HIV-2+patients compared with HIV-1+patients: a multinational, multicohort European study
Wittkop L; Arsandaux J; Trevino A; van der Loeff MS; Anderson J; van Sighem A; Boni J; Brun-Vezinet F; Soriano V; Boufassa F; Brockmeyer N; Calmy A; Dabis F; Jarrin I; Dorrucci M; Duque V; Faetkenheuer G; Zangerle R; Ferrer E; Porter K; Judd A; Sipsas NV; Lambotte O; Shepherd L; Leport C; Morrison C; Mussini C; Obel N; Ruelle J; Schwarze-Zander C; Sonnerborg A; Teira R; Torti C; Valadas E; Colin C; Friis-Moller N; Costagliola D; Thiebaut R; Chene G; Matheron S
Article: HIV MEDICINE. 2017;18(9):677-684
A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model
Brannstrom J; Sonnerborg A; Svedhem V; Neogi U; Marrone G
Article: BJOG: AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2017;124(11):1680-1687
Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study
Carlander C; Marrone G; Brannstrom J; Yilmaz A; Elfgren K; Sparen P; Sonnerborg A
Article: SCIENTIFIC REPORTS. 2017;7(1):6371
Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden
Neogi U; Siddik AB; Kalaghatgi P; Gisslen M; Bratt G; Marrone G; Sonnerborg A
Article: SCIENTIFIC REPORTS. 2017;7(1):6269
Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers
Vesterbacka J; Rivera J; Noyan K; Parera M; Neogi U; Calle M; Paredes R; Sonnerborg A; Noguera-Julian M; Nowak P
Article: CLINICAL INFECTIOUS DISEASES. 2017;64(12):1644-1656
The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges
Gourlay A; Noori T; Pharris A; Axelsson M; Costagliola D; Cowan S; Croxford S; Monforte AD; del Amo J; Delpech V; Diaz A; Girardi E; Gunsenheimer-Bartmeyer B; Hernando V; Jose S; Leierer G; Nikolopoulos G; Obel N; de Coul EO; Paraskeva D; Reiss P; Sabin C; Sasse A; Schmid D; Sonnerborg A; Spina A; Suligoi B; Supervie V; Touloumi G; Van Beckhoven D; van Sighem A; Vourli G; Zangerle R; Porter K
Article: SCIENTIFIC REPORTS. 2017;7(1):666
Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
Zhang W; Morshed MM; Noyan K; Russom A; Sonnerborg A; Neogi U
Article: HIV MEDICINE. 2017;18(4):305-307
Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets
Gisslen M; Svedhem V; Lindborg L; Flamholc L; Norrgren H; Wendahl S; Axelsson M; Sonnerborg A
Article: VIRUS EVOLUTION. 2017;3(Suppl 1):vew036.020
A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.
Vinken L; Fransen K; Pineda-Peña AC; Alexiev I; Balotta C; Debaisieux L; Devaux C; García Ribas S; Gomes P; Incardona F; Kaiser R; Ruelle J; Sayan M; Paraschiv S; Paredes R; Peeters M; Sonnerborg A; Vancutsem E; Van den Wijngaert S; Van Ranst M; Verhofstede C; Vandamme A-M; Lemey P; Van Laethem K
Article: SCIENTIFIC REPORTS. 2017;7:40354
Perturbed CD8⁺ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren H-G; Sonnerborg A; Lund O; Reyes-Teran G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Article: BMC INFECTIOUS DISEASES. 2017;17(1):37
Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort
Kalu AW; Telele NF; Gebreselasie S; Fekade D; Abdurahman S; Marrone G; Sonnerborg A
Article: PLOS ONE. 2017;12(8):e0182384
Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort
Kalu AW; Telele NF; Gebreselasie S; Fekade D; Abdurahman S; Marrone G; Sonnerborg A
Article: PLOS ONE. 2017;12(7):e0180140
Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients
Haggblom A; Santacatterina M; Neogi U; Gisslen M; Hejdeman B; Flamholc L; Sonnerborg A
Article: JOURNAL OF MEDICAL VIROLOGY. 2017;89(1):106-111
Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa
Aralaguppe SG; Winner D; Singh K; Sarafianos SG; Quinones-Mateu ME; Soennerborg A; Neogi U
Article: PLOS ONE. 2017;12(6):e0178942
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy
Svard J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sonnerborg A
Article: BMC INFECTIOUS DISEASES. 2016;16(1):759
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam
Do DC; Sonnerborg A; Vu VT; El-Khatib Z; Santacatterina M; Marrone G; Nguyen TKC; Diwan V; Thorson A; Le NK; Pham NA; Larsson M
Article: INFECTION, GENETICS AND EVOLUTION. 2016;46:169-179
The global spread of HIV-1 subtype B epidemic
Magiorkinis G; Angelis K; Mamais I; Katzourakis A; Hatzakis A; Albert J; Lawyer G; Hamouda O; Struck D; Vercauteren J; Wensing A; Alexiev I; Asjo B; Balotta C; Gomes P; Camacho RJ; Coughlan S; Griskevicius A; Grossman Z; Horban A; Kostrikis LG; Lepej SJ; Liitsola K; Linka M; Nielsen C; Otelea D; Paredes R; Poljak M; Puchhammer-Stoekl E; Schmit JC; Sonnerborg A; Stanekova D; Stanojevic M; Stylianou DC; Boucher CAB; Nikolopoulos G; Vasylyeva T; Friedman SR; van de Vijver D; Angarano G; Chaix M-L; de Luca A; Korn K; Loveday C; Soriano V; Yerly S; Zazzi M; Vandamme A-M; Paraskevis D
Article: CLINICAL INFECTIOUS DISEASES. 2016;63(9):1245-1253
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.
Pediatric AIDS-Defining Cancer Project Working Gro; Rohner E; Schmidlin K; Zwahlen M; Chakraborty R; Clifford G; Obel N; Grabar S; Verbon A; Noguera-Julian A; Collins IJ; Rojo P; Brockmeyer N; Campbell M; Chêne G; Prozesky H; Eley B; Stefan DC; Davidson A; Chimbetete C; Sawry S; Davies M-A; Kariminia A; Vibol U; Sohn A; Egger M; Bohlius J
Article: JOURNAL OF VIROLOGICAL METHODS. 2016;236:98-104
Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus
Aralaguppe SG; Siddik AB; Manickam A; Ambikan AT; Kumar MM; Fernandes SJ; Amogne W; Bangaruswamy DK; Hanna LE; Sonnerborg A; Neogi U
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(7):1471-1479
Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden
Carlander C; Wagner P; Svedhem V; Elfgren K; Westling K; Sonnerborg A; Sparen P
Article: HIV MEDICINE. 2016;17(8):590-600
Infection-related and -unrelated malignancies, HIV and the aging population.
Shepherd L; Borges Á; Ledergerber B; Domingo P; Castagna A; Rockstroh J; Knysz B; Tomazic J; Karpov I; Kirk O; Lundgren J; Mocroft A; EuroSIDA in EuroCOORD
Article: BMC INFECTIOUS DISEASES. 2016;16:305
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
Sorstedt E; Nilsson S; Blaxhult A; Gisslen M; Flamholc L; Sonnerborg A; Yilmaz A
Article: HIV MEDICINE. 2016;17(6):425-435
Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden
Brannstrom J; Johansson VS; Marrone G; Wendahl S; Yilmaz A; Blaxhult A; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2016;32(5):471-474
Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster
Amogne W; Bontell I; Grossmann S; Aderaye G; Lindquist L; Sonnerborg A; Neogi U
Article: THE LANCET INFECTIOUS DISEASES. 2016;16(5):565-575
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
Gregson J; Tang M; Ndembi N; Hamers RL; Rhee S-Y; Marconi VC; Diero L; Brooks K; Theys K; de Wit TFR; Arruda M; Garcia F; Monge S; Gunthard HF; Hoffmann CJ; Kanki PJ; Kumarasamy N; Kerschberger B; Mor O; Charpentier C; Todesco E; Rokx C; Gras L; Halvas EK; Sunpath H; Di Carlo D; Antinori A; Andreoni M; Latini A; Mussini C; Aghokeng A; Sonnerborg A; Neogi U; Fessel WJ; Agolory S; Yang C; Blanco JL; Juma JM; Smit E; Schmidt D; Watera C; Asio J; Kirungi W; Tostevin A; El-Hay T; Clumeck N; Goedhals D; van Vuuren C; Bester PA; Sabin C; Mukui I; Santoro MM; Perno CF; Hunt G; Morris L; Camacho R; de Oliveira T; Pillay D; Schulter E; Murakami-Ogasawara A; Reyes-Teran G; Romero K; Avila-Rios S; Sirivichayakul S; Ruxrungtham K; Mekprasan S; Dunn D; Kaleebu P; Raizes E; Kantor R; Shafer RW; Gupta RK
Article: THE LANCET HIV. 2016;3(4):e166-e174
Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
Haggblom A; Svedhem V; Singh K; Sonnerborg A; Neogi U
Article: CLINICAL INFECTIOUS DISEASES. 2016;62(5):655-663
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Asjo B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stoeckl E; Sonnerborg A; Stanekova D; Stanojevic M; Van Laethem K; Zazzi M; Lepej SZ; Boucher CAB; Schmit J-C; Wensing AMJ
Article: EBIOMEDICINE. 2016;5:135-146
Gut Microbiota Linked to Sexual Preference and HIV Infection
Noguera-Julian M; Rocafort M; Guillen Y; Rivera J; Casadella M; Nowak P; Hildebrand F; Zeller G; Parera M; Bellido R; Rodriguez C; Carrillo J; Mothe B; Coll J; Bravo I; Estany C; Herrero C; Saz J; Sirera G; Torrela A; Navarro J; Crespo M; Brander C; Negredo E; Blanco J; Guarner F; Luz Calle M; Bork P; Sonnerborg A; Clotet B; Paredes R
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;71(2):367-371
Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries
Neogi U; Haggblom A; Singh K; Rogers LC; Rao SD; Amogne W; Schuelter E; Zazzi M; Arnold E; Sarafianos SG; Sonnerborg A
Article: PLOS ONE. 2016;11(9):e0162503
Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study
Brannstrom J; Svedhem V; Marrone G; Andersson O; Azimi F; Blaxhult A; Sonnerborg A
Article: VIRUS EVOLUTION. 2016;2(1):vew010
HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries
Esbjornsson J; Mild M; Audelin A; Fonager J; Skar H; Jorgensen LB; Liitsola K; Bjorkman P; Bratt G; Gisslen M; Sonnerborg A; Nielsen C; Medstrand P; Albert J
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2016;32(1):80-84
Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa
Neogi U; Engelbrecht S; Claassen M; Jacobs GB; van Zyl G; Preiser W; Sonnerborg A
Article: THE LANCET HIV. 2016;3(1):e23-e32
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte AD; Kirk O; Ryom L; Data Collection on Adverse events of Anti-HIV Drug
Article: CLINICAL IMMUNOLOGY. 2015;161(2):180-189
Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection
Svard J; Paquin-Proulx D; Buggert M; Noyan K; Barqasho B; Sonnerborg A; Nowak P
Article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2015;70(4):329-337
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART
Stiksrud B; Nowak P; Nwosu FC; Kvale D; Thalme A; Sonnerborg A; Ueland PM; Holm K; Birkeland S-E; Dahm AEA; Sandset PM; Rudi K; Hov JR; Dyrhol-Riise AM; Troseid M
Article: AIDS. 2015;29(18):2409-2418
Gut microbiota diversity predicts immune status in HIV-1 infection
Nowak P; Troseid M; Avershina E; Barqasho B; Neogi U; Holm K; Hov JR; Noyan K; Vesterbacka J; Svard J; Rudi K; Sonnerborg A
Article: LIVER INTERNATIONAL. 2015;35(11):2384-2391
Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?
Boesecke C; Grint D; Soriano V; Lundgren JD; d'Arminio Monforte A; Mitsura VM; Chentsova N; Hadziosmanovic V; Kirk O; Mocroft A; Peters L; Rockstroh JK; EuroSIDA in EuroCoord
Article: HIV MEDICINE. 2015;16(9):533-543
Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study.
Podlekareva D; Grint D; Karpov I; Rakmanova A; Mansinho K; Chentsova N; Zeltina I; Losso M; Parczewski M; Lundgren JD; Mocroft A; Kirk O; EuroSIDA in EuroCoord
Article: PLOS PATHOGENS. 2015;11(8):e1005072
Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection
Leeansyah E; Svard J; Dias J; Buggert M; Nystrom J; Quigley MF; Moll M; Sonnerborg A; Nowak P; Sandberg JK
Article: AIDS. 2015;29(11):1379-1389
HIV resistance testing and detected drug resistance in Europe.
Schultze A; Phillips AN; Paredes R; Battegay M; Rockstroh JK; Machala L; Tomazic J; Girard PM; Januskevica I; Gronborg-Laut K; Lundgren JD; Cozzi-Lepri A; EuroSIDA in EuroCOORD
Article: AIDS. 2015;29(10):1205-1215
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.
Grint D; Peters L; Rockstroh JK; Rakmanova A; Trofimova T; Lacombe K; Karpov I; Galli M; Domingo P; Kirk O; Lundgren JD; Mocroft A; EuroSIDA in EuroCoord
Article: JOURNAL OF INFECTIOUS DISEASES. 2015;211(11):1735-1744
Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia
Angelis K; Albert J; Mamais I; Magiorkinis G; Hatzakis A; Hamouda O; Struck D; Vercauteren J; Wensing AMJ; Alexiev I; Asjo B; Balotta C; Camacho RJ; Coughlan S; Griskevicius A; Grossman Z; Horban A; Kostrikis LG; Lepej S; Liitsola K; Linka M; Nielsen C; Otelea D; Paredes R; Poljak M; Puchhammer-Stockl E; Schmit J-C; Sonnerborg A; Stanekova D; Stanojevic M; Boucher CAB; Kaplan L; Vandamme A-M; Paraskevis D
Article: HIV MEDICINE. 2015;16(5):297-306
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data
Vingerhoets J; Calvez V; Flandre P; Marcelin A-G; Ceccherini-Silberstein F; Perno C-F; Santoro MM; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Guenthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M
Article: PLOS ONE. 2015;10(5):e0122587
Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
Article: PLOS ONE. 2015;10(9):e0137635
Multidimensional Clusters of CD4+T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection
Frederiksen J; Buggert M; Noyan K; Nowak P; Sonnerborg A; Lund O; Karlsson AC
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2014;69(12):3349-3355
Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries
Ekici H; Rao SD; Sonnerborg A; Ramprasad VL; Gupta R; Neogi U
Article: AIDS. 2014;28(15):2319-2322
Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients
Neogi U; Rao SD; Bontell I; Verheyen J; Rao VR; Gore SC; Soni N; Shet A; Schuelter E; Ekstrand ML; Wondwossen A; Kaiser R; Madhusudhan MS; Prasad VR; Sonnerborg A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(9):624-632
High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort
Stenkvist J; Weiland O; Sonnerborg A; Blaxhult A; Falconer K
Article: INFECTION. 2014;42(4):757-762
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
Mocroft A; Reiss P; Rakhmanova A; Banhegyi D; Phillips AN; De Wit S; Ristola M; Lundgren JD; Grarup J; Kirk O; EuroSIDA in EuroCOORD
Article: BMC INFECTIOUS DISEASES. 2014;14:407
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe
Frentz D; Van de Vijver DAMC; Abecasis AB; Albert J; Hamouda O; Jorgensen LB; Kucherer C; Struck D; Schmit J-C; Vercauteren J; Asjo B; Balotta C; Beshkov D; Camacho RJ; Clotet B; Coughlan S; Griskevicius A; Grossman Z; Horban A; Kolupajeva T; Korn K; Kostrikis LG; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stockl E; Sonnerborg A; Stanekova D; Stanojevic M; Van Wijngaerden E; Wensing AMJ; Boucher CAB
Article: JOURNAL OF INFECTIOUS DISEASES. 2014;210(2):234-243
Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons
Shepherd L; Souberbielle J-C; Bastard J-P; Fellahi S; Capeau J; Reekie J; Reiss P; Blaxhult A; Bickel M; Leen C; Kirk O; Lundgren JD; Mocroft A; Viard J-P
Article: PLOS PATHOGENS. 2014;10(7):e1004251
T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+T Cells in HIV Infection
Buggert M; Tauriainen J; Yamamoto T; Frederiksen J; Ivarsson MA; Michaelsson J; Lund O; Hejdeman B; Jansson M; Sonnerborg A; Koup RA; Betts MR; Karlsson AC
Article: AIDS. 2014;28(5):727-737
Deteriorating renal function and clinical outcomes in HIV-positive persons.
Mocroft A; Ryom L; Begovac J; Monforte AD; Vassilenko A; Gatell J; Florence E; Ormaasen V; Kirk O; Lundgren JD; EuroSIDA in EuroCOORD
Article: JOURNAL OF IMMUNOLOGY. 2014;192(5):2099-2108
Multiparametric Bioinformatics Distinguish the CD4/CD8 Ratio as a Suitable Laboratory Predictor of Combined T Cell Pathogenesis in HIV Infection
Buggert M; Frederiksen J; Noyan K; Svard J; Barqasho B; Nnerborg AS; Lund O; Nowak P; Karlsson AC
Article: AIDS. 2014;28(4):577-587
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
Grint D; Peters L; Rockstroh JK; de Wit S; Mitsura VM; Knysz B; Pedersen C; Kirk O; Lundgren JD; Mocroft A; EuroSIDA in EuroCoord
Article: PLOS ONE. 2014;9(10):e111042
Minority Drug-Resistant HIV-1 Variants in Treatment Naive East-African and Caucasian Patients Detected by Allele-Specific Real-Time PCR
Ekici H; Amogne W; Aderaye G; Lindquist L; Sonnerborg A; Abdurahman S
Article: PLOS ONE. 2014;9(4):e94495
Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group
Frentz D; van de Vijver D; Abecasis A; Albert J; Hamouda O; Jorgensen L; Kucherer C; Struck D; Schmit J-C; Vercauteren J; Asjo B; Balotta C; Bergin C; Beshkov D; Camacho R; Clotet B; Griskevicius A; Grossman Z; Horban A; Kolupajeva T; Korn K; Kostrikis L; Linka KLM; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stoeckl E; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme A-M; Boucher C; Wensing A
Article: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2014;17(1):18841
Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden
Abdurahman S; Barqasho B; Nowak P; Do DC; Amogne W; Larsson M; Lindquist L; Marrone G; Sonnerborg A
Article: PLOS ONE. 2014;9(7):e101508
Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
Agneskog E; Nowak P; Steffensson CM; Casadella M; Noguera-Julian M; Paredes R; Kallander CFR; Sonnerborg A
Article: PLOS ONE. 2014;9(6):e99390
Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades
Neogi U; Haggblom A; Santacatterina M; Bratt G; Gisslen M; Albert J; Sonnerborg A
Article: BMC INFECTIOUS DISEASES. 2013;13:537
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
Bartha I; Assel M; Sloot PMA; Zazzi M; Torti C; Schuelter E; De Luca A; Sonnerborg A; Abecasis AB; Van Laethem K; Rosi A; Svard J; Paredes R; van de Vijver DAMC; Vandamme A-M; Mueller V
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(11):770-778
Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
Ackefors M; Nystrom J; Wernerson A; Gjertsen H; Sonnerborg A; Weiland O
Article: INFECTION, GENETICS AND EVOLUTION. 2013;19:349-360
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
Sangeda RZ; Theys K; Beheydt G; Rhee S-Y; Deforche K; Vercauteren J; Libin P; Imbrechts S; Grossman Z; Camacho RJ; Van Laethem K; Pironti A; Zazzi M; Sonnerborg A; Incardona F; De Luca A; Torti C; Ruiz L; Van de Vijver DAMC; Shafer RW; Bruzzone B; Van Wijngaerden E; Vandamme A-M
Article: INFECTION, GENETICS AND EVOLUTION. 2013;18:125-131
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys
Andersson E; Shao W; Bontell I; Cham F; Do DC; Wondwossen A; Morris L; Hunt G; Sonnerborg A; Bertagnolio S; Maldarelli F; Jordan MR
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(7):543-551
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
Andersson L-M; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sonnerborg A; Gisslen M
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;207(Suppl 2):S101-S106
Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs
Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sonnerborg A; Nachega JB
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;207(8):1216-1220
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe
De Luca A; Dunn D; Zazzi M; Camacho R; Torti C; Fanti I; Kaiser R; Sonnerborg A; Codoner FM; Van Laethem K; Vandamme A-M; Bansi L; Ghisetti V; van de Vijver DAMC; Asboe D; Prosperi MCF; Di Giambenedetto S
Article: RETROVIROLOGY. 2013;10:36
Limited cross-border infections in patients newly diagnosed with HIV in Europe
Frentz D; Wensing AMJ; Albert J; Paraskevis D; Abecasis AB; Hamouda O; Jorgensen LB; Kuecherer C; Struck D; Schmit J-C; Asjo B; Balotta C; Beshkov D; Camacho RJ; Clotet B; Coughlan S; De Wit S; Griskevicius A; Grossman Z; Horban A; Kolupajeva T; Korn K; Kostrikis LG; Liitsola K; Linka M; Nielsen C; Otelea D; Paredes R; Poljak M; Puchhammer-Stoeckl E; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme A-M; Boucher CAB; Van de Vijver DAMC
Article: JOURNAL OF MEDICAL VIROLOGY. 2013;85(4):703-708
Evaluation of etravirine resistance in clinical samples by a simple phenotypic Test
Agneskog E; Nowak P; Kallander CFR; Sonnerborg A
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(3):193-199
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism
Stenkvist J; Sonnerborg A; Weiland O
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2013;29(3):564-573
Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection
Jansen K; Sonnerborg A; Brockmeyer N; Thalme A; Svedhem V; Dupke S; Eychenne J-L; Nakonz T; Jimenez-Exposito MJ; Pugliese P
Article: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2013;16(1):18472
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals
Neogi U; Shet A; Sahoo PN; Bontell I; Ekstrand ML; Banerjea AC; Sonnerborg A
Article: BLOOD. 2013;121(7):1124-1135
Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection
Leeansyah E; Ganesh A; Quigley MF; Sonnerborg A; Andersson J; Hunt PW; Somsouk M; Deeks SG; Martin JN; Moll M; Shacklett BL; Sandberg JK
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2013;57(2):1053-1056
HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir
Theys K; Vercauteren J; Snoeck J; Zazzi M; Camacho RJ; Torti C; Schuelter E; Clotet B; Soennerborg A; De Luca A; Grossman Z; Struck D; Vandamme A-M; Abecasis AB
Article: RETROVIROLOGY. 2013;10:7
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Abecasis AB; Wensing AMJ; Paraskevis D; Vercauteren J; Theys K; de Vijver DAMCV; Albert J; Asjo B; Balotta C; Beshkov D; Camacho RJ; Clotet B; De Gascun C; Griskevicius A; Grossman Z; Hamouda O; Horban A; Kolupajeva T; Korn K; Kostrikis LG; Kuecherer C; Liitsola K; Linka M; Nielsen C; Otelea D; Paredes R; Poljak M; Puchhammer-Stoeckl E; Schmit J-C; Sonnerborg A; Stanekova D; Stanojevic M; Struck D; Boucher CAB; Vandamme A-M
Article: AIDS RESEARCH AND TREATMENT. 2013;2013:731983-3
AIDS and HIV Infection after Thirty Years.
Ippolito G; Levy JA; Sonnerborg A; Mugusi F; Dianzani F
Article: PLOS ONE. 2013;8(8):e72257
HIV Care in the Swedish-Danish HIV Cohort 1995-2010, Closing the Gaps
Helleberg M; Haggblom A; Sonnerborg A; Obel N
Article: PLOS ONE. 2013;8(4):e61436
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
Vercauteren J; Beheydt G; Prosperi M; Libin P; Imbrechts S; Camacho R; Clotet B; De Luca A; Grossman Z; Kaiser R; Sonnerborg A; Torti C; Van Wijngaerden E; Schmit J-C; Zazzi M; Geretti A-M; Vandamme A-M; Van Laethem K
Article: PLOS ONE. 2013;8(3):e59337
Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997-2011
Bontell I; Haggblom A; Bratt G; Albert J; Sonnerborg A
Article: PLOS ONE. 2013;8(1):e55421
Long-Term Efficacy of First Line Antiretroviral Therapy in Indian HIV-1 Infected Patients: A Longitudinal Cohort Study
Neogi U; Heylen E; Shet A; Chandy S; Shamsunder R; Soennerborg A; Ekstrand ML
Article: PLOS ONE. 2013;8(1):e55038
Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
Vesterbacka J; Nowak P; Barqasho B; Abdurahman S; Nystrom J; Nilsson S; Funaoka H; Kanda T; Andersson L-M; Gisslen M; Sonnerborg A
Article: PLOS ONE. 2013;8(1):e52845
Feasibility and Effectiveness of Indicator ConditionGuided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)
Sullivan AK; Raben D; Reekie J; Rayment M; Mocroft A; Esser S; Leon A; Begovac J; Brinkman K; Zangerle R; Grzeszczuk A; Vassilenko A; Hadziosmanovic V; Krasnov M; Sonnerborg A; Clumeck N; Gatell J; Gazzard B; Monforte AD; Rockstroh J; Lundgren JD
Article: PLOS ONE. 2013;8(11):e79193
Molecular Dating of HIV-1 Subtype C from Bangladesh
Bontell I; Sarker MS; Rahman M; Afrad MH; Sonnerborg A; Azim T
Article: RETROVIROLOGY. 2012;9:81
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
Theys K; Deforche K; Vercauteren J; Libin P; van de Vijver DAMC; Albert J; Asjo B; Balotta C; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Hamouda O; Horban A; Korn K; Kostrikis LG; Kucherer C; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stockl E; Riva C; Ruiz L; Liitsola K; Schmit J-C; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Struck D; Van Laethem K; Wensing AMJ; Boucher CAB; Vandamme A-M
Article: FUTURE VIROLOGY. 2012;7(9):923-931
Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam
Do DC; Agneskog E; Chuc NTK; Santacafferina M; Sonnerborg A; Mattias L
Article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2012;59(4):347-353
Higher Prevalence of Predicted X4-Tropic Strains in Perinatally Infected Older Children With HIV-1 Subtype C in India
Neogi U; Sahoo PN; Arumugam K; Sonnerborg A; De Costa A; Shet A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(3):201-208
Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam
Do DC; Thorson A; Sonnerborg A; Nguyen PH; Nguyen TKC; Ho DP; Larsson M
Article: INFECTION, GENETICS AND EVOLUTION. 2012;12(2):448-452
Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam
Bontell I; Do DC; Agneskog E; Diwan V; Larsson M; Sonnerborg A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(2):108-114
Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study
Dalgaard LS; Sogaard OS; Jensen-Fangel S; larsen CS; Sonnerborg A; Ostergaard L
Article: INTERNATIONAL JOURNAL OF MICROBIOLOGY. 2012;2012:263836-10
Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection.
Nowak P; Abdurahman S; Lindkvist A; Troseid M; Sönnerborg A
Article: PLOS ONE. 2012;7(3):e33484
Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003-2010
Karlsson A; Bjoerkman P; Bratt G; Ekvall H; Gisslen M; Soennerborg A; Mild M; Albert J
Article: INTERVIROLOGY. 2012;55(2):160-166
Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort
Oette M; Schuelter E; Rosen-Zvi M; Peres Y; Zazzi M; Soennerborg A; Struck D; Altmann A; Kaiser R
Article: INTERVIROLOGY. 2012;55(2):123-127
Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project
Zazzi M; Incardona F; Rosen-Zvi M; Prosperi M; Lengauer T; Altmann A; Sonnerborg A; Lavee T; Schuelter E; Kaiser R
Article: PLOS ONE. 2012;7(7):e39874
Characterization of HIV-Specific CD4+T Cell Responses against Peptides Selected with Broad Population and Pathogen Coverage
Buggert M; Norstrom MM; Czarnecki C; Tupin E; Luo M; Gyllensten K; Sonnerborg A; Lundegaard C; Lund O; Nielsen M; Karlsson AC
Article: PLOS ONE. 2012;7(6):e39819
Molecular Epidemiology of HIV-1 Subtypes in India: Origin and Evolutionary History of the Predominant Subtype C
Neogi U; Bontell I; Shet A; De Costa A; Gupta S; Diwan V; Laishram RS; Wanchu A; Ranga U; Banerjea AC; Sonnerborg A
Article: AAPS JOURNAL. 2011;13(4):598-605
Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
Rekic D; Clewe O; Roshammar D; Flamholc L; Sonnerborg A; Ormaasen V; Gisslen M; Abelo A; Ashton M
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2011;66(8):1886-1896
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
Prosperi MCF; Mackie N; Di Giambenedetto S; Zazzi M; Camacho R; Fanti I; Torti C; Soennerborg A; Kaiser R; Codoner FM; Van Laethem K; Bansi L; van de Vijver DAMC; Geretti AM; De Luca A
Article: AIDS RESEARCH AND THERAPY. 2011;8:26
HIV-1 mutational pathways under multidrug therapy
Lawyer G; Altmann A; Thielen A; Zazzi M; Sonnerborg A; Lengauer T
Article: AIDS RESEARCH AND THERAPY. 2011;8:21
Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
Mellberg T; Gonzalez VD; Lindkvist A; Eden A; Sonnerborg A; Sandberg JK; Svennerholm B; Gisslen M
Article: HIV MEDICINE. 2011;12(4):246-249
Overcoming obstacles to late presentation for HIV infection in Europe
Lazarus JV; Juergens R; Weait M; Phillips A; Hows J; Gatell J; Coenen T; Sonnerborg A; Raben D; Lundgren JD
Article: HIV MEDICINE. 2011;12(4):211-218
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)
Zazzi M; Kaiser R; Sonnerborg A; Struck D; Altmann A; Prosperi M; Rosen-Zvi M; Petroczi A; Peres Y; Schuelter E; Boucher CA; Brun-Vezinet F; Harrigan PR; Morris L; Obermeier M; Perno C-F; Phanuphak P; Pillay D; Shafer RW; Vandamme A-M; van Laethem K; Wensing AMJ; Lengauer T; Incardona F
Article: AIDS REVIEWS. 2011;13(2):77-108
European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update
Vandamme A-M; Camacho RJ; Ceccherini-Silberstein F; de Luca A; Palmisano L; Paraskevis D; Paredes R; Poljak M; Schmit J-C; Soriano V; Walter H; Sonnerborg A
Article: CURRENT HIV RESEARCH. 2011;9(1):6-10
High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation
Troseid M; Sonnerborg A; Nowak P
Article: HIV MEDICINE. 2011;12(1):61-64
Late presentation of HIV infection: a consensus definition
Antinori A; Coenen T; Costagiola D; Dedes N; Ellefson M; Gatell J; Girardi E; Johnson M; Kirk O; Lundgren J; Mocroft A; Monforte AD; Phillips A; Raben D; Rockstroh JK; Sabin C; Sonnerborg A; de Wolf F
Article: PLOS ONE. 2010;5(10):e13753
Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
Prosperi MCF; Rosen-Zvi M; Altmann A; Zazzi M; Di Giambenedetto S; Kaiser R; Schuelter E; Struck D; Sloot P; van de Vijver DA; Vandamme A-M; Sonnerborg A
Article: AIDS. 2010;24(11):1733-1737
Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy
Troseid M; Nowak P; Nystrom J; Lindkvist A; Abdurahman S; Sonnerborg A
Article: JOURNAL OF GENERAL VIROLOGY. 2010;91(Pt 7):1800-1809
Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro
Barqasho B; Nowak P; Abdurahman S; Walther-Jallow L; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2010;26(5):533-540
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naive HIV-1-Infected Patients
Eden A; Andersson L-M; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Sall C; Sonnerborg A; Tunback P; Gisslen M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(4):349-357
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na⟨ve HIV-1 infected patients
Josephson F; Andersson MCH; Flamholc L; Gisslen M; Hagberg L; Ormaasen V; Sonnerborg A; Vesterbacka J; Bottiger Y
Article: PLOS ONE. 2010;5(2):e9044
Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
Weisser H; Altmann A; Sierra S; Incardona F; Struck D; Sonnerborg A; Kaiser R; Zazzi M; Tschochner M; Walter H; Lengauer T
Article: JOURNAL OF INFECTIOUS DISEASES. 2009;200(10):1503-1508
Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe
Vercauteren J; Wensing AMJ; van de Vijver DAMC; Albert J; Balotta C; Hamouda O; Kuecherer C; Struck D; Schmit J-C; Asjo B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stoeckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme A-M; Boucher CAB
Article: AIDS RESEARCH AND THERAPY. 2009;6:15
Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.
Lindkvist A; Edén A; Norström MM; Gonzalez VD; Nilsson S; Svennerholm B; Karlsson AC; Sandberg JK; Sönnerborg A; Gisslén M
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2009;39(3):902-911
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection
Moll M; Kuylenstierna C; Gonzalez VD; Andersson SK; Bosnjak L; Sonnerborg A; Quigley MF; Sandberg JK
Article: HIV MEDICINE. 2009;10(2):111-115
Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma
Bergroth T; Ekici H; Gisslen M; Hagberg L; Sonnerborg A
Article: HIV MEDICINE. 2009;10(2):94-102
Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption
Barqasho B; Nowak P; Tjernlund A; Kinloch S; Goh L-E; Lampe F; Fisher M; Andersson J; Sonnerborg A
Article: JOURNAL OF MEDICAL VIROLOGY. 2009;81(1):1-8
Selection of Drug-Resistant HIV-1 During the Early Phase of Viral Decay Is Uncommon in Treatment-Naive Patients Initiated on a Three- or Four-Drug Antiretroviral Regimen Including Lamivudine
Bergroth T; Ekici H; Gisslen M; Kinloch-de Loes S; Goh L-E; Freedman A; Lampe F; Johnson MA; Sonnerborg A
Article: ANTIVIRAL THERAPY. 2009;14(3):433-442
Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment
Prosperi MCF; Altmann A; Rosen-Zvi M; Aharoni E; Gabor B; Fulop B; Sonnerborg A; Schuelter E; Struck D; Ulivi G; Vandamme A-M; Vercauteren J; Zazzi M
Article: ANTIVIRAL THERAPY. 2009;14(2):273-283
Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype
Altmann A; Sing T; Vermeiren H; Winters B; Van Craenenbroeck E; Van der Borght K; Rhee S-Y; Shafer RW; Schuelter E; Kaiser R; Peres Y; Sonnerborg A; Fessel WJ; Incardona F; Zazzi M; Bacheler L; Van Vlijmen H; Lengauer T
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(8):775-781
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels
Josephson F; Bertilsson L; Bottiger Y; Flamholc L; Gisslen M; Ormaasen V; Sonnerborg A; Diczfalusy U
Article: AIDS. 2008;22(7):899-901
Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy.
Karlström O; Sönnerborg A; Weiland O
Article: AIDS. 2008;22(5):625-635
Transmission of drug-resistant HIV-1 in Europe remains limited to single classes
Wensing AMJ; Vercauteren J; van de Vijver DA; Albert J; Asjo B; Balotta C; Camacho R; Coughlan S; Grossman Z; Horban A; Kucherer C; Nielsen C; Paraskevis D; Loke WC; Poggensee G; Puchhammer-Stockl E; Riva C; Ruiz L; Schmit J-C; Schuurman R; Salminen M; Sonnerborg A; Stanojevic M; Struck D; Vandamme A-M; Boucher CAB
Article: GHANA MEDICAL JOURNAL. 2008;42(1):16-21
Virological Characterization of Dual HIV-1/HIV-2 Seropositivity and Infections in Southern Ghana.
Sagoe K; Mingle J; Affram R; Britton S; Dzokoto A; Sonnerborg A
Article: PLOS ONE. 2008;3(10):e3470
Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy
Altmann A; Rosen-Zvi M; Prosperi M; Aharoni E; Neuvirth H; Schuelter E; Buech J; Struck D; Peres Y; Incardona F; Soennerborg A; Kaiser R; Zazzi M; Lengauer T
Article: HIV MEDICINE. 2007;8(8):504-510
Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure
Svedhem V; Bergroth T; Lidman K; Sonnerborg A
Article: PATIENT EDUCATION AND COUNSELING. 2007;67(1-2):108-116
A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment
Sodergard B; Hofer S; Halvarsson M; Sonnerborg A; Tully MP; Lindblad AK
Article: AIDS. 2007;21(7):869-871
Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection
Nowak P; Barqasho B; Sonnerborg A
Article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2007;44(4):417-422
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy
Karlstrom O; Josephson F; Sonnerborg A
Article: AIDS. 2007;21(5):565-574
Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection
Nilsson J; Kinloch-de-Loes S; Granath A; Sonnerborg A; Goh L-E; Andersson J
Article: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2006;31(6):605-616
Adherence to treatment in Swedish HIV-infected patients
Sodergard B; Halvarsson M; Tully MP; Mindouri S; Nordstrom M-L; Lindback S; Sonnerborg A; Lindblad AK
Article: PHARMACY WORLD AND SCIENCE. 2006;28(4):248-256
Differences in adherence and motivation to HIV therapy -: two independent assessments in 1998 and 2002
Sodergard B; Halvarsson M; Lindback S; Sonnerborg A; Tully MP; Lindblad AK
Article: CYTOKINE. 2006;34(1-2):17-23
HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages
Nowak P; Barqasho B; Treutiger CJ; Harris HE; Tracey KJ; Andersson J; Sönnerborg A
Article: PHARMACOGENETICS AND GENOMICS. 2006;16(3):191-198
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
Wang J; Sonnerborg A; Rane A; Josephson F; Lundgren S; Stahle L; Ingelman-Sundberg M
Article: AIDS. 2006;20(1):11-19
Early induction of leukemia inhibitor factor (LIF) in acute HIV-1 infection
Tjernlund A; Barqasho B; Nowak P; Kinloch S; Thorborn D; Perrin L; Sönneborg A; Walther-Jallow L; Andersson J
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2006;38(5):371-374
Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients
Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2006;38(2):86-103
Antiretroviral treatment of HIV infection:: Swedish recommendations 2005
Gisslén M; Ahlqvist-Rastad J; Albert J; Blaxhult A; Hamberg AK; Lindbäck S; Sandström E; Uhnoo I; Sönnerborg A
Article: JOURNAL OF INFECTIOUS DISEASES. 2005;192(4):607-617
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Copper DA; Perrin L
Article: JOURNAL OF MEDICAL VIROLOGY. 2005;76(4):447-451
Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
Article: JOURNAL OF VIROLOGICAL METHODS. 2005;127(1):100-107
Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR
Bergroth T; Sönnerborg A; Yun ZB
Article: BLOOD. 2004;104(12):3672-3678
Expansion of CD7^low and CD7^negative CD8 T-cell effector subsets in HIV-1 infection:: correlation with antigenic load and reversion by antiretroviral treatment
Aandahl EM; Quigley MF; Moretto WJ; Moll M; Gonzalez VD; Sönnerborg A; Lindbäck S; Hecht FM; Deeks SG; Rosenberg MG; Nixon DF; Sandberg JK
Article: THERAPEUTIC DRUG MONITORING. 2004;26(3):267-270
Efavirenz plasma concentrations in HIV-infected patients -: Inter- and intraindividual variability and clinical effects
Stähle L; Moberg L; Svensson JO; Sönnerborg A
Article: BLOOD. 2004;103(6):2180-2186
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection
De Milito A; Nilsson A; Titanji K; Thorstensson R; Reizenstein E; Narita M; Grutzmeier S; Sönnerborg A; Chiodi F
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;106(1):35-39
Site-directed serology of HIV-1 subtype B infection: Relation between virus specific antibody levels and disease progression
Brostrom C; Sonnerborg A; Kim S; Sallberg M
Article: VIROLOGY. 2003;314(1):179-189
Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner
Naghavi MH; Nowak P; Andersson J; Sönnerborg A; Yang H; Tracey KJ; Vahlne A
Article: AIDS. 2003;17(10):1463-1471
Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing
Shao XW; Malmsten A; Lennerstrand J; Sönnerborg A; Unge T; Gronowitz JS; Källander CFR
Article: AIDS. 2003;17(9):1303-1310
Suppression of leukemia inhibitor factor in lymphoid tissue in primary HIV infection:: absence of HIV replication in gp130-positive cells
Tjernlund A; Fleener Z; Behbahani H; Connick E; Sönnerborg A; Broström C; Goh LE; Spetz AL; Patterson BK; Andersson J
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;132(2):297-303
Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection
Titanji K; Nilsson A; Mörch C; Samuelsson A; Sönnerborg A; Grutzmeier S; Zazzi M; De Milito A
Article: JOURNAL OF MEDICAL VIROLOGY. 2003;69(2):195-201
Inter-laboratory comparison of HCV-RNA assay results:: Implications for multi-centre research
Pembrey L; Newell ML; Tovo PA; van Drimmelen H; Quinti I; Furlini G; Galli S; Meliconi MG; Burns S; Hallam N; Sönnerborg A; Cilla G; Serrano E; Laccetti P; Portella G; Polywka S; Icardi G; Bruzzone B; Balbo L; Alfarano A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2003;35(3):155-167
Antiretroviral treatment of human immunodeficiency virus infection:: Swedish recommendations
Sandström E; Uhnoo I; Ahlqvist-Rastad J; Bratt G; Berglund T; Gisslén M; Lindbäck S; Morfeldt L; Ståhle L; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2003;19(1):13-19
Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection
Nowak P; Schvarcz R; Ericzon BG; Flamholc L; Sönnerborg A
Article: EUROPEAN JOURNAL OF PAIN. 2003;7(1):23-31
Painful and non-painful neuropathy in HIV-infected patients:: an analysis of somatosensory nerve function
Martin C; Solders G; Sönnerborg A; Hansson P
Article: JOURNAL OF MEDICAL VIROLOGY. 2002;68(4):473-478
Persistence of earlier HIV-1 drug resistance mutations at new treatment failure
Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
Article: LAKARTIDNINGEN. 2002;99(43):4263-4266
[Swedish guidelines for antiretroviral treatment of HIV. Good compliance is crucial for a good result].
Gisslén M; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2002;18(10):727-732
Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya
Visco-Comandini U; Cappiello G; Liuzzi G; Tozzi V; Anzidei G; Abbate I; Amendola A; Bordi L; Budabbus MA; Eljhawi OA; Mehabresh MI; Girardi E; Antinori A; Capobianchi MR; Sönnerborg A; Ippolito G
Article: AIDS. 2002;16(7):1039-1044
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;127(3):486-494
Plasma levels of soluble CD27:: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects
De Milito A; Aleman S; Marenzi R; Sönnerborg A; Fuchs D; Zazzi M; Chiodi F
Article: AIDS. 2002;16(5):683-692
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
Loré K; Sönnerborg A; Broström C; Goh LE; Perrin L; McDade H; Stellbrink HJ; Gazzard B; Weber R; Napolitano LA; van Kooyk Y; Andersson J
Article: AIDS. 2002;16(1):97-104
Level and pattern of HIV-1-RNA viral load over age:: differences between girls and boys?
Giaquinto C; Rampon O; Giacomet V; Rossi AD; Grosch-Wörner I; Mok J; Bates I; de José I; Hawkins F; Garcia-Rodriguez MC; de Guevara CL; Peña JM; Garcia JG; Lopez JRA; Asensi-Botet F; Otero MC; Pérez-Tamarit D; Orti A; San Miguel MJ; de la Torre R; Scherpbier H; Kreyenbroek K; Boer K; Bohlin AB; Belfrage E; Navér L; Ehrnst A; Sönnerborg A; Levy J; Hainaut M; Peltier A; Wibaut S; Barlow P; Ferrazin A; Bassetti D; De Maria A; Gotta C; Mûr A; Payà A; Viñolas M; López-Vilchez MA; Rovira M; Carreras R; Tores EE; Perez SH; Valerius NH; Newell ML; Gray L; Thorne C; Cortina-Borja M; Peckham C
Article: HIV MEDICINE. 2002;3(1):1-11
The selection and evolution of viral quasispecies in HIV-1 infected children.
Nowak P; Karlsson AC; Naver L; Bohlin AB; Piasek A; Sönnerborg A
Article: JOURNAL OF INFECTIOUS DISEASES. 2001;184(11):1392-1401
Recent origin of human immunodeficiency virus type 1 variants in resting CD4⁺ T lymphocytes in untreated and suboptimally treated subjects
Karlsson AC; Lindkvist A; Lindbäck S; Gaines H; Sönnerborg A
Article: AIDS. 2001;15(11):1359-1368
Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy
Birk M; Svedhem V; Sönnerborg A
Article: JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS. 2001;15(3):299-303
Human immunodeficiency virus type 1 variability and long-term non-progression
Visco-Comandini U; Aleman S; Yun Z; Sönnerborg A
Article: AIDS. 2001;15(8):957-964
Loss of memory (CD27) B lymphocytes in HIV-1 infection
De Milito A; Mörch C; Sönnerborg AS; Chiodi F
Article: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 2001;20(3):159-166
Broad spectrum of time of detection, primary symptoms and disease progression in infants with HIV-1 infection
Navér L; Ehrnst A; Belfrage E; Blomberg J; Christensson B; Forsgren M; Lidin-Janson G; Lindgren S; Ljung R; Sönnerborg A; Bohlin AB
Article: MOLECULAR THERAPY. 2001;3(4):531-535
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1
Maijgren-Steffensson C; Sönnerborg A; Vahlne A; Britton S; Larsson S; Ährlund-Richter L
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2001;17(5):409-416
Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution
Karlsson AC; Birk M; Lindbäck S; Gaines H; Mittler JE; Sönnerborg A
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2001;249(1-2):207-222
Quantitative single cell methods that identify cytokine and chemokine expression in dendritic cells
Loré K; Spetz AL; Fehniger TE; Sönnerborg A; Landay AL; Andersson J
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2001;33(5):323-328
Management of infections caused by respiratory syncytial virus
Rastad AA; Andersson J; Beermann B; Bohlin AB; Brandt C; Eriksson M; Ewald U; Göthberg S; Lind A; Lindroth M; Ljungman P; Navér L; Norrby SR; Pauksen K; Ransjö U; Rebbel H; Östlund MR; Sigurs N; Ståhle L; Säwe J; Sönnerborg A; Uhnoo I; Stopner B
Article: AIDS. 2000;14(15):2333-2339
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure
Lindbäck S; Thorstensson R; Karlsson AC; von Sydow M; Flamholc L; Blaxhult A; Sönnerborg A; Biberfeld G; Gaines H
Article: AIDS. 2000;14(15):2283-2291
Viral dynamics in primary HIV-1 infection
Lindbäck S; Karlsson AC; Mittler J; Blaxhult A; Carlsson M; Briheim G; Sönnerborg A; Gaines H
Article: HIV MEDICINE. 2000;1(4):205-211
Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.
Birk M; Aleman S; Visco-Comandini U; Sönnerborg A
Article: THERAPEUTIC DRUG MONITORING. 2000;22(5):637-638
Switching antiretroviral therapy from an enzyme-inducing drug
Gyllensten K; Sönnerborg A; Ståhle L
Article: THERAPEUTIC DRUG MONITORING. 2000;22(5):626-629
Rapid and simple determination of indinavir in serum, urine, and cerebrospinal fluid using high-performance liquid chromatography
Svensson JO; Sönnerborg A; Ståhle L
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2000;16(14):1379-1384
High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy
De Milito A; Hejdeman B; Albert J; Aleman S; Sönnerborg A; Zazzi M; Chiodi F
Article: LAKARTIDNINGEN. 2000;97(28-29):3275-3279
[Mother-to-child transmission of HIV infections. Antiviral agents and Cesarean section reduce the risk of transmission].
Bohlin AB; Lindgren S; Lidman K; Sönnerborg A
Article: NEUROLOGY. 2000;54(11):2120-2127
Antiretroviral therapy may improve sensory function in HIV-infected patients
Martin C; Solders G; Sönnerborg A; Hansson P
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2000;7(3):377-383
Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies
Iroegbu J; Birk M; Lazdina U; Sönnerborg A; Sällberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2000;32(5):465-470
Chronic hepatitis C -: Swedish experts' meeting recommends combination treatment
Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerborg A; Uhnoo I; Weiland O
Article: LAKARTIDNINGEN. 1999;96(44):4795-4800
[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].
Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerborg A; Uhnoo I; Weiland O
Article: AIDS. 1999;13(15):2013-2021
HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation
Loré K; Sönnerborg A; Olsson J; Patterson BK; Fehniger TE; Perbeck L; Andersson J
Article: AIDS. 1999;13(14):1921-1925
HIV viral load and response to antileishmanial chemotherapy in co-infected patients
Berhe N; Wolday D; Hailu A; Abraham Y; Ali A; Gebre-Michael T; Desjeux P; Sönnerborg A; Akuffo H; Britton S
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(14):1293-1303
Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1
Naghavi MH; Schwartz S; Sönnerborg A; Vahlne A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(14):1249-1254
Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels
Aleman S; Visco-Comandini U; Loré K; Sönnerborg A
Article: AIDS. 1999;13(11):1295-1303
Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection
Andersson J; Behbahani H; Lieberman J; Connick E; Landay A; Patterson B; Sönnerborg A; Loré K; Uccini S; Fehniger TE
Article: AIDS. 1999;13(10):1227-1232
Indinavir-based treatment of HIV-1 infected patients:: efficacy in the central nervous system
Martin C; Sönnerborg A; Svensson JO; Ståhle L
Article: JOURNAL OF VIROLOGY. 1999;73(7):6191-6196
Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
Karlsson AC; Gaines H; Sällberg M; Lindbäck S; Sönnerborg A
Article: EUROPEAN JOURNAL OF PAIN. 1999;3(2):157-164
Pain in ambulatory HIV-infected patients with and without intravenous drug use
Martin C; Pehrsson P; Österberg A; Sönnerborg A; Hansson P
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(8):775-779
Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana
Sagoe KWC; Britton S; Mingle JAA; Affram K; Djokoto A; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(7):647-653
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients
Björndal Å; Sönnerborg A; Tscherning C; Albert J; Fenyö EM
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(7):609-617
No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects
Visco-Comandini U; Yun ZB; Vahlne A; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999;15(5):485-488
DNA sequence of the long terminal repeat of human immunodeficiency virus type I subtype A through G
Naghavi MH; Salminen MO; Sönnerborg A; Vahlne A
Article: GUT. 1999;44(2):274-278
Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products
Halasz R; Barkholt L; Lara C; Hultgren C; Ando Y; Broomé U; Fischler B; Nemeth A; Ericzon BG; Sönnerborg A; Sällberg M
Article: GASTROENTEROLOGY. 1999;116(1):135-143
Limited humoral immunity in hepatitis C virus infection
Chen M; Sällberg M; Sönnerborg A; Weiland O; Mattsson L; Jin L; Birkett A; Peterson D; Milich DR
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1999;31(1):93-95
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination
Carlsson T; Struve J; Sönnerborg A; Weiland O
Article: ANTIVIRAL THERAPY. 1999;4(2):109-115
Kinetics of β-chemokine levels during anti-HIV therapy
Aleman S; Pehrson P; Sonnerborg A
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1999;31(4):337-343
Long-term pattern of HIV-1 RNA load in perinatally infected children
Navér L; Ehrnst A; Belfrage E; Sönnerborg A; Lidin-Janson G; Christensson B; Ljung R; Bohlin AB
Article: AIDS. 1998;12(18):2369-2375
Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
Birk M; Sönnerborg A
Article: AIDS. 1998;12(16):F203-F209
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
Article: AIDS. 1998;12(15):2007-2015
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
Schmit JC; Van Laethem K; Ruiz L; Hermans P; Sprecher S; Sonnerborg A; Leal M; Harrer T; Clotet B; Arendt V; Lissen E; Witvrouw M; Desmyter J; De Clercq E; Vandamme AM
Article: AIDS. 1998;12(15):1973-1981
Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity
Birk M; Flock JI; Sönnerborg A; Sallberg M
Article: IMMUNOGENETICS. 1998;48(6):417-419
Distribution of the CCR5 gene 32 base pair deletion and SDF1-3′A variant in healthy individuals from different populations
Magierowska M; Lepage V; Boubnova L; Carcassi C; de Juan D; Djoulah S; El Chenawi F; Grunnet N; Hallé L; Ivanova R; Jungerman M; Naumova E; Petrany G; Sonnerborg A; Stavropoulos C; Thorsby E; Vu-Trieu A; Debré P; Theodorou I; Charron D
Article: BONE MARROW TRANSPLANTATION. 1998;22(5):499-501
Detection of hepatitis G virus GB virus C after allogeneic bone marrow transplantation
Ljungman P; Halasz R; Hägglund H; Sönnerborg A; Ringdén O
Article: CLINICAL AND VACCINE IMMUNOLOGY. 1998;5(5):662-666
Low relative frequencies of CD26⁺ CD4⁺ cells in long-term nonprogressing human immunodeficiency virus type 1-infected subjects
Brostrom C; Sonnerborg A; Lindback S; Gaines H
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1998;36(9):2454-2459
Cooperative oligonucleotides mediating direct capture of hepatitis C virus RNA from serum
O'Meara D; Yun ZB; Sönnerborg A; Lundeberg J
Article: JOURNAL OF MEDICAL VIROLOGY. 1998;56(1):33-38
Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
Odeberg J; Yun ZB; Sönnerborg A; Weiland O; Lundeberg J
Article: JOURNAL OF HUMAN VIROLOGY. 1998;1(5):320-327
HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study.
Visco-Comandini U; Yun Z; Paganelli R; Orlandi P; Salotti A; Johansson B; Vahlne A; Sönnerborg A
Article: HEPATOLOGY. 1998;28(1):219-224
Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein
Chen M; Sällberg M; Sönnerborg A; Jin L; Birkett A; Peterson D; Weiland O; Milich DR
Article: AIDS. 1998;12(8):839-847
Characterization of the viral population during primary HIV-1 infection
Karlsson AC; Lindbäck S; Gaines H; Sönnerborg A
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 1998;214(1-2):97-111
Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells
Loré K; Sönnerborg A; Spetz AL; Andersson U; Andersson J
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1998;18(1):51-53
Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection
Bergdahl S; Jacobsson B; Moberg L; Sönnerborg A
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1998;17(3):214-219
Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels
Martin C; Albert J; Hansson P; Pehrsson PO; Link H; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1998;14(3):241-248
Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules.
Birk M; Vahlne A; Sönnerborg A; Sällberg M
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1998;14(3):289-292
Full-length sequence of human immunodeficiency virus type 1 subtype A, recombined with subtype C in the env V3 domain
Sherefa K; Johansson B; Salminen M; Sönnerborg A
Article: THE LANCET. 1998;351(9096):83-87
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1998;36(1):255-257
Detection of hepatitis G virus RNA in persons with and without known risk factors for blood-borne viral infections in Sweden and Honduras
Lara C; Halasz R; Sönnerborg A; Sällberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1998;30(5):441-446
Comparison of 3 quantitative HCV RNA assays -: Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Article: THE LANCET. 1997;350(9094):1823
Indinavir in cerebrospinal fluid of HIV-1-infected patients
Ståhle L; Martin C; Svensson JO; Sönnerborg A
Article: JOURNAL OF VIROLOGICAL METHODS. 1997;69(1-2):171-180
Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR
Comandini UV; Sönnerborg A; Vahlne A; Yun ZB
Article: VIROLOGY. 1997;238(2):180-188
Apoptosis of CD4(+) and CD19(+) cells during human immunodeficiency virus type 1 infection - correlation with clinical progression, viral load, and loss of humoral immunity
Samuelsson A; Brostrom C; vanDijk N; Sonnerborg A; Chiodi F
Article: EUROPEAN JOURNAL OF NEUROLOGY. 1997;4(6):576-585
Cerebrospinal fluid analyses in HIV patients: a longitudinal study through six years
Pirskanen R; Samuelsson K; Sonnerborg A; Waldenlind L; Sandstrom E
Article: LAKARTIDNINGEN. 1997;94(40):3519-3523
[Hepatitis GBV isolated in acute liver failure. Successful outcome after liver transplantation].
Broomé U; Ericzon BG; Eleborg L; Stål P; Oksanen A; Sönnerborg A
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(9):2419-2421
Subtyping of human immunodeficiency virus type 1 strains by using antibodies specific for the third variable domain (V3) of gp120, results may be affected by divergent V3 sequences
Sherefa K; Sallberg M; Johansson B; Salminen M; Sonnerborg A
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1997;15(5):381-386
Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994
Krook A; Albert J; Andersson S; Biberfeld G; Blomberg J; Eklund I; Engstrom A; Julander I; Kall K; Martin C; Stendahl P; Struve J; Sonnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1997;13(12):1031-1038
Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection
Samuelsson A; Sonnerborg A; Heuts N; Coster J; Chiodi F
Article: TRANSPLANTATION. 1997;64(1):170-172
Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation
Yun ZB; Barkholt L; Sonnerborg A
Article: JOURNAL OF INFECTIOUS DISEASES. 1997;176(1):281-285
Genetic evidence for mother-to-infant transmission of hepatitis G virus
Fischler B; Lara C; Chen M; Sonnerborg A; Nemeth A; Sallberg M
Article: AIDS. 1997;11(7):859-865
Subtype-specific problems with quantification of plasma HIV-1 RNA
Alaeus A; Lidman K; Sonnerborg A; Albert J
Article: RESEARCH IN VIROLOGY. 1997;148(3):233-237
Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions
Yun Z; Johansson B; Weiland O; Sonnerborg A
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(4):973-975
Detection of hepatitis G virus (GB virus C) RNA in human saliva
Chen M; Sonnerborg A; Johansson B; Sallberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 1997;175(4):938-943
Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients
Odeberg J; Yun ZB; Sonnerborg A; Bjoro K; Uhlen M; Lundeberg J
Article: INFECTION. 1997;25(2):74-77
Nosocomial transmission of hepatitis C virus.
Schvarcz R; Johansson B; Nyström B; Sönnerborg A
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1997;13(4):343-345
Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993
Sonnerborg A; Durdevic S; Giesecke J; Sallberg M
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1997;35(3):783-784
The Honduran human immunodeficiency virus type 1 (HIV-1) epidemic is dominated by HIV-1 subtype B as determined by V3 domain sero- and genotyping
Lara C; Sallberg M; Johansson B; deRivera IL; Sonnerborg A
Article: CLINICAL AND VACCINE IMMUNOLOGY. 1997;4(1):104-106
Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function
Ando Y; Sonnerborg A; Barkholt L; Birkett A; Ericzon BG; Sallberg M
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1996;12(14):1329-1339
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C.
Salminen MO; Johansson B; Sönnerborg A; Ayehunie S; Gotte D; Leinikki P; Burke DS; McCutchan FE
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1996;50(6):457-461
Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: A double blind placebo controlled trial
Akerlund B; Jarstrand C; Lindeke B; Sonnerborg A; Akerblad AC; Rasool O
Article: JOURNAL OF MEDICAL VIROLOGY. 1996;49(3):155-160
Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences
Yun AB; Lara C; Johansson B; deRivera IL; Sonnerborg A
Article: VIROLOGY. 1996;219(1):161-169
A novel ribozyme target site located in the HIV-1 Nef open reading frame
Larsson S; Hotchkiss G; Su J; Kebede T; Andang M; Nyholm T; Johansson B; Sonnerborg A; Vahlne A; Britton S; Ährlund-Richter L
Article: JOURNAL OF INFECTIOUS DISEASES. 1996;173(4):992-996
Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load
Yun ZB; Odeberg J; Lundeberg J; Weiland O; Uhlen M; Sonnerborg A
Article: LAKARTIDNINGEN. 1995;92(46):4331-4334
[Parvovirus B19 infection in different shapes. But more laboratories have refined the diagnostic methods].
Jorup C; Gyllensten K; Persson A; Forsgren M; Sönnerborg A
Article: BLOOD. 1995;86(4):1614-1618
LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS
LJUNGMAN P; JOHANSSON N; ASCHAN J; GLAUMANN H; LONNQVIST B; RINGDEN O; SPARRELID E; SONNERBORG A; WINIARSKI J; GAHRTON G
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 1995;33(7):1870-1874
DYNAMIC ANALYSIS OF HETEROGENEOUS HEPATITIS-C VIRUS POPULATIONS BY DIRECT SOLID-PHASE SEQUENCING
ODEBERG J; YUN ZB; SONNERBORG A; UHLEN M; LUNDEBERG J
Article: JOURNAL OF MEDICAL VIROLOGY. 1995;46(1):43-47
COMBINED TREATMENT WITH INTERFERON-ALPHA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS-C IN PATIENTS WITH A PREVIOUS NONRESPONSE OR NONSUSTAINED RESPONSE TO INTERFERON ALONE
SCHVARCZ R; YUN ZB; SONNERBORG A; WEILAND O
Article: HEPATOLOGY. 1995;21(4):918-922
2-YEAR BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGICAL FOLLOW-UP IN PATIENTS WITH CHRONIC HEPATITIS-C RESPONDING IN A SUSTAINED FASHION TO INTERFERON ALFA-2B TREATMENT
REICHARD O; GLAUMANN H; FRYDEN A; NORKRANS G; SCHVARCZ R; SONNERBORG A; YUN ZB; WEILAND O
Article: JOURNAL OF MEDICAL VIROLOGY. 1995;45(2):223-226
DETECTION OF HEPATITIS-C VIRUS-RNA IN THE CELL FRACTION OF SALIVA BEFORE AND AFTER ORAL-SURGERY
CHEN M; YUN ZB; SALLBERG M; SCHVARCZ R; BERGQUIST I; BERGLUND HB; SONNERBORG A
Article: JOURNAL OF HEPATOLOGY. 1995;23:17-21
Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
Schvarcz R; Ando Y; Sonnerborg A; Weiland O
Article: JOURNAL OF MEDICAL VIROLOGY. 1995;45(1):50-55
EVALUATION OF A MULTIPLE PEPTIDE ASSAY FOR TYPING OF ANTIBODIES TO THE HEPATITIS-C VIRUS - RELATION TO GENOMIC TYPING BY THE POLYMERASE CHAIN-REACTION
ZHANG ZX; YUN ZB; CHEN M; SONNERBORG A; SALLBERG M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(4):319-324
EFFICACY OF HUMAN-LEUKOCYTE ALPHA-INTERFERON TREATMENT FOR CHRONIC HEPATITIS-C VIRUS-INFECTION
WEILAND O; CHEN M; LINDH G; MATTSSON L; SCHVARCZ R; SONNERBORG A; WAHL M; WEJSTAL R
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(5):449-452
TRANSMISSION OF HEPATITIS-C VIRUS BY TRANSFUSION IN OREBRO COUNTY, SWEDEN, 1990-1992
NORDA R; DUBERG AS; SONNERBORG A; OLCEN P
Visa fler

Alla övriga publikationer

Review: DRUG RESISTANCE UPDATES. 2023;68:100955
Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide
Cena-Diez R; Spetz A-L; Sonnerborg A
Other: CLINICAL CASE REPORTS. 2022;10(2):e05373
Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients
Kuznetsova A; Lebedev A; Gromov K; Kazennova E; Zazzi M; Incardona F; Sonnerborg A; Bobkova M
Review: EXPERT OPINION ON THERAPEUTIC PATENTS. 2021;31(4):339-350
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents
Spratt AN; Gallazzi F; Quinn TP; Lorson CL; Sonnerborg A; Singh K
Preprint: BIORXIV. 2021;BIORXIV
Factors Associated with Emerging and Re-emerging of SARS-CoV-2 Variants.
Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sönnerborg A; Byrareddy SN; Singh K
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;289(3):434-436
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
Eimer J; Vesterbacka J; Svensson A-K; Stojanovic B; Wagrell C; Sonnerborg A; Nowak P
Review: INFECTIOUS DISEASES. 2021;53(1):1-8
Contagiousness in treated HIV-1 infection
Eriksen J; Albert J; Axelsson M; Berglund T; Brannstrom J; Gaines H; Gisslen M; Groon P; Hagstam P; Naver L; Pettersson K; Stenkvist J; Sonnerborg A; Tegnell A
Letter: JOURNAL OF NEUROIMMUNE PHARMACOLOGY. 2020;15(4):574-577
Infectivity of SARS-CoV-2: there Is Something More than D614G?
Kannan SR; Spratt AN; Quinn TP; Heng X; Lorson CL; Sonnerborg A; Byrareddy SN; Singh K
Review: JOURNAL OF PROTEOME RESEARCH. 2020;19(11):4259-4274
Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses
Sperk M; van Domselaar R; Rodriguez JE; Mikaeloff F; Vinhas BS; Saccon E; Sonnerborg A; Singh K; Gupta S; Vegvari A; Neogi U
Review: INFECTIOUS DISEASES. 2020;52(5):295-329
Antiretroviral treatment for HIV infection: Swedish recommendations 2019
Eriksen J; Carlander C; Albert J; Flamholc L; Gisslen M; Naver L; Svedhem V; Yilmaz A; Sonnerborg A
Meeting abstract: VIRUS EVOLUTION. 2019;5:S2
Near full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden
Andersson E; Aralaguppe S; Thebo L; Sonnerborg A; Neogi U; Albert J
Review: PHARMACEUTICALS. 2019;12(2):E62-62
Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Singh K; Sarafianos SG; Sonnerborg A
Review: INFECTIOUS DISEASES. 2018;50(7):495-506
Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017
Naver L; Albert J; Carlander C; Flamholc L; Gisslen M; Karlstrom O; Svedhem-Johansson V; Sonnerborg A; Westling K; Yilmaz A; Pettersson K
Letter: EUROSURVEILLANCE. 2017;22(11):30483-28
Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance
van Tienen C; van de Vijver D; Noori T; Sonnerborg A; Boucher C
Review: INFECTIOUS DISEASES. 2017;49(1):1-34
Antiretroviral treatment for HIV infection: Swedish recommendations 2016
Eriksen J; Albert J; Blaxhult A; Carlander C; Flamholc L; Gisslen M; Josephson F; Karlstrom O; Naver L; Svedhem V; Yilmaz A; Sonnerborg A
Review: INFECTIOUS DISEASES. 2016;48(2):93-98
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Gaines H; Albert J; Axelsson M; Berglund T; Gisslen M; Sonnerborg A; Blaxhult A; Bogdanovic G; Brytting M; Carlander C; Flamholc L; Follin P; Haggar A; Hagstam P; Johansson M; Naver L; Blom JP; Samuelson A; Strom H; Sundqvist M; Johansson VS; Wisell KT; Tegnell A; Thorstensson R
Corrigendum: AIDS. 2015;29(2):251
Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C: Erratum (vol 28, pg 2635, 2014)
Neogi U; Sonnerborg A
Letter: AIDS. 2014;28(17):2635-2636
Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C
Neogi U; Sonnerborg A
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(10):673-677
Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Albert J; Berglund T; Gisslen M; Groon P; Sonnerborg A; Tegnell A; Alexandersson A; Berggren I; Blaxhult A; Brytting M; Carlander C; Carlson J; Flamholc L; Follin P; Haggar A; Hansdotter F; Josephson F; Karlstrom O; Liljeros F; Naver L; Pettersson K; Johansson VS; Svennerholm B; Tunback P; Widgren K
Review: JOURNAL OF HEPATOLOGY. 2014;61(4):957-961
Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals
Stenkvist J; Nystrom J; Faconer K; Sonnerborg A; Weiland O
Review: VIRUSES. 2014;6(9):3535-3562
Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
Singh K; Flores JA; Kirby KA; Neogi U; Sonnerborg A; Hachiya A; Das K; Arnold E; McArthur C; Parniak M; Sarafianos SG
Letter: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2014;66(4):e87-e89
On the Usefulness of Circulating Bacterial 16S rDNA as a Marker of Microbial Translocation in HIV-1-Infected Patients
Svard J; Sonnerborg A; Vondracek M; Molling P; Nowak P
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(6):401-411
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013
Naver L; Albert J; Bottiger Y; Carlander C; Flamholc L; Gisslen M; Josephson F; Karlstrom O; Lindborg L; Svedhem-Johansson V; Svennerholm B; Sonnerborg A; Yilmaz A; Pettersson K
Meeting abstract: JOURNAL OF HEPATOLOGY. 2014;60(1):S327
LOWER UPTAKE OF HCV TREATMENT THAN HIV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS
Stenkvist J; Weiland O; Sonnerborg A; Blaxhult A; Falconer K
Meeting abstract: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2014;17(4 Suppl 3):19790-182
Time on drug analysis based on real life data
Schuelter E; Kaiser R; Zazzi M; Soennerborg A; Camacho R; Verheyen J
Review: FUTURE VIROLOGY. 2012;7(8):749-757
Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics
Svard J; Sonnerborg A
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2011;43(6-7):411-423
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
Naver L; Albert J; Belfrage E; Flamholc L; Gisslen M; Gyllensten K; Josephson F; Karlstrom O; Lindgren S; Pettersson K; Svedhem V; Sonnerborg A; Westling K; Yilmaz A
Review: THE LANCET INFECTIOUS DISEASES. 2011;11(5):394-407
European guidelines on the clinical management of HIV-1 tropism testing
Vandekerckhove LPR; Wensing AMJ; Kaiser R; Brun-Vezinet F; Clotet B; De Luca A; Dressler S; Garcia F; Geretti AM; Klimkait T; Korn K; Masquelier B; Perno CF; Schapiro JM; Soriano V; Sonnerborg A; Vandamme A-M; Verhofstede C; Walter H; Zazzi M; Boucher CAB; Puchhammer-Stockl E; Van Laethem K; Ivanov IA; Beshkov DA; Lepej SZ; Kostrikis LG; Linka M; Nielsen C; Zilmer K; Liitsola K; Braun P; Daeumer M; Obermeier M; Paraskevis D; Minarovits J; Coughlin S; de Gascun C; Grossman Z; Balotta C; Rusconi S; Svicher V; Kolupajeva T; Griskevicius A; Schmit J-CC; Schuurman R; Asjo B; Horban AJW; Camacho RJ; Ene L; Otelea D; Stanojevic M; Stanekova D; Poljak M; Paredes R; Poveda E; Albert J; Yerly S; Cane P; Pillay D
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2009;199(7):999-1006
Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database
Altmann A; Daeumer M; Beerenwinkel N; Peres Y; Schuelter E; Buech J; Rhee S-Y; Soennerborg A; Fessel WJ; Shafer RW; Zazzi M; Kaiser R; Lengauer T
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2009;41(11-12):788-807
Treatment of HIV infection: Swedish recommendations 2009
Josephson F; Albert J; Flamholc L; Gisslen M; Karlstrom O; Moberg L; Naver L; Svedhem V; Svennerholm B; Sonnerborg A
Published conference paper: BIOINFORMATICS. 2008;24(13):i399-i406
Selecting anti-HIV therapies based on a variety of genomic and clinical factors
Rosen-Zvi M; Altmann A; Prosperi M; Aharoni E; Neuvirth H; Sonnerborg A; Schuelter E; Struck D; Peres Y; Incardona F; Kaiser R; Zazzi M; Lengauer T
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2008;40(6-7):451-461
Prophylaxis and treatment of HIV-1 infection in pregnancy:: Swedish recommendations 2007
Naver L; Bohlin A-B; Albert J; Flamholc L; Gisslen M; Gyllensten K; Josephson F; Pehrson P; Sonnerborg A; Westling K; Lindgren S
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2008;40(6-7):436-450
Treatment of chronic hepatitis B infection:: An update of Swedish recommendations
Lindh M; Uhnoo I; Blackberg J; Duberg A-S; Friman S; Fischler B; Karlstrom O; Norkrans G; Reichard O; Sangfeldt P; Soderstrom A; Sonnerborg A; Weiland O; Wejstal R; Wistrom J
Letter: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2007;46(1):118-119
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy -: Reply
Karlstrom O; Josephson F; Sonnerborg A
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2007;39(6-7):486-507
Antiretroviral treatment of HIV infection:: Swedish recommendations 2007
Josephson F; Albert J; Flamholc L; Gisslen M; Karlstroem O; Lindgren S-R; Navter L; Sandstroem E; Svedhem-Johansson V; Svennerholm B; Soennerborg A
Review: PATIENT EDUCATION AND COUNSELING. 2006;62(1):21-30
Assessing and achieving readiness to initiate HIV medication
Nordqvist O; Sodergard B; Tully MP; Sonnerborg A; Lindblad AK
Review: ANTIVIRAL THERAPY. 2004;9(6):829-848
Updated European recommendations for the clinical use of HIV drug resistance testing
Vandamme AM; Sönnerborg A; Ait-Khaled M; Albert J; Asjo B; Bacheler L; Banhegyi D; Boucher C; Brun-Vézinet F; Camacho R; Clevenbergh P; Clumeck N; Dedes N; De Luca A; Doerr HW; Faudon JL; Gatti G; Gerstoft J; Hall WW; Hatzakis A; Hellmann N; Horban A; Lundgren JD; Kempf D; Miller M; Miller V; Myers TW; Nielsen C; Opravil M; Palmisano L; Perno CF; Phillips A; Pillay D; Pumarola T; Ruiz L; Salminen M; Schapiro J; Schmidt B; Schmit JC; Schuurman R; Shulse E; Soriano V; Staszewski S; Vella S; Youle M; Ziermann R; Perrin L
Corrigendum: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;134(1):167
Plasma levels of soluble CD27:: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects (vol 127, pg 486, 2002)
De Milito A; Aleman S; Marenzi R; Sönnerborg A; Fuchs D; Zazzi M; Chiodi F
Editorial comment: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, SUPPLEMENT. 2003;35:5
Use of genotypic assays for the detection of antiretroviral resistance:: a legal proceeding, Rome, 22-23 April 2002 -: Guest editor introduction
Sönnerborg A
Letter: JOURNAL OF CLINICAL MICROBIOLOGY. 2002;40(10):3883-3884
Quantification of human immunodeficiency virus type I proviral DNA by the TaqMan real-time PCR assay
Yun ZB; Fredriksson E; Sönnerborg A
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2002;185(9):1355-1358
Low levels of perforin expression in CD8⁺ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
Andersson J; Kinloch S; Sönnerborg A; Nilsson J; Fehniger TE; Spetz AL; Behbahani H; Goh LE; McDade H; Gazzard B; Stellbrink H; Cooper D; Perrin L
Editorial comment: VACCINE. 2002;20(15):1895
Special issue:: NOBEL SYMPOSIUM 119 -: Global HIV Therapeutics -: HIV Vaccines Nobel Forum, Karolinska Institutet, June 7-9, 2001 -: Foreword
Lijeström P; Andersson J; Sönnerborg A
Review: ANTIVIRAL THERAPY. 2001;6(1):21-39
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
Vandamme AM; Houyez F; Bànhegyi D; Clotet B; De Schrijver G; De Smet KAL; Hall WW; Harrigan R; Hellmann N; Hertogs K; Holtzer C; Larder B; Pillay D; Race E; Schmit JC; Schuurman R; Shulse E; Sönnerborg A; Miller V
Review: AIDS. 2001;15(3):309-320
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.
EuroGuidelines Group for HIV Resistance
Letter: NATURE MEDICINE. 2000;6(11):1194
The Quest Trial, a paradigm of HIV collaborative research
Goh LE; McDade H; Kinloch S; Perrin L; Cooper D; Phillips A; Hoen B; Autran B; Sonnerborg A; Tsoukas C
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 1999;179(6):1542-1548
Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors
Broström C; Visco-Comandini U; Yun ZB; Sönnerborg A
Review: LAKARTIDNINGEN. 1998;95(42):4562-4564
[Treatment of HIV infections--an update. The easy work is done--the difficult is still to be done].
Sönnerborg A; Pehrsson P
Corrigendum: JOURNAL OF IMMUNOLOGICAL METHODS. 1998;218(1-2):173-187
Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells (vol 214, pg 97, 1998)
Loré K; Sönnerborg A; Spetz AL; Andersson U; Andersson J
Letter: ANTIVIRAL THERAPY. 1998;3(4):233-234
Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV
Schvarcz R; Moberg L; Sönnerborg A
Letter: AIDS. 1997;11(15):1897
HIV-1 subtype C epidemic in Ethiopia
Sonnerborg A; Sherefa K
Letter: LAKARTIDNINGEN. 1997;94(17):1589-1590
[Measurement of HIV-RNA in blood is of great predictive value].
Sönnerborg A
Other: LAKARTIDNINGEN. 1996;93(6):451-452
[News about HIV. Combination therapy with new drugs gives hope].
Sönnerborg A; Julander I
Letter: GENITOURINARY MEDICINE. 1995;71(5):323-324
HIV-INFECTION AND MATERNAL OUTCOME OF PREGNANCY IN MOZAMBICAN WOMEN - A CASE-CONTROL STUDY
BERGSTROM S; SONNERBORG A; OSMAN NB; LIBOMBO A
Letter: THE LANCET. 1995;346(8968):190
Prevention of nosocomial transmission of hepatitis C virus.
Schvarcz R; Nyström B; Oksanen A; Sönnerborg A
Other: AIDS RESEARCH AND HUMAN RETROVIRUSES. 1995;11(6):761-764
MULTIPLE ENHANCER MOTIFS IN HIV TYPE-1 STRAINS FROM ETHIOPIA
JOHANSSON B; SHEREFA K; SONNERBORG A
Other: JOURNAL OF INFECTIOUS DISEASES. 1995;171(5):1356-1359
DISTINGUISHING ACUTE FROM SYMPTOMATIC CHRONIC HEPATITIS-C VIRUS (HCV) INFECTION BY SITE-DIRECTED SEROLOGY OF THE HCV STRUCTURAL PROTEINS
ZHANG ZX; CHEN M; SONNERBORG A; WEILAND O; SALLBERG M
Other: JOURNAL OF CLINICAL MICROBIOLOGY. 1995;33(3):778-780
LEVELS OF HEPATITIS-C VIRUS (HCV) RNA IN SERUM AND THEIR RELATIONSHIP TO LEVELS OF IMMUNOGLOBULIN-M AND IMMUNOGLOBULIN-G ANTIBODIES AGAINST HCV CORE PROTEIN
CHEN M; SONNERBORG A; SALLBERG M
Letter: JOURNAL OF INFECTIOUS DISEASES. 1995;171(2):509-511
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PATIENTS WITH NO DISEASE PROGRESSION DISPLAY HIGH-AVIDITY ANTIBODY-PRODUCTION TO AUTOLOGOUS V3 SEQUENCES
BROSTROM C; SONNERBORG A; SALLBERG M
Addendum: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(5):319-324
Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
Other: CLINICAL AND VACCINE IMMUNOLOGY. 1995;2(1):118-119
ELEVATED LEVELS OF CIRCULATING TUMOR-NECROSIS-FACTOR-ALPHA IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED AFRICANS LIVING IN SWEDEN
SONNERBORG A; AYEHUNIE S; JULANDER I
Visa fler

Forskningsbidrag

COMPARE - Comprehensive Morbidity PostCovid Assessment using Registries
Swedish Research Council
1 December 2021 - 30 November 2025
Characterization of susceptibility and resistance to novel categories of anti-HIV compounds
Swedish Research Council
1 January 2021 - 31 December 2023
Antiviral compounds against CoV-2 helicase
Swedish Research Council
1 August 2020 - 31 December 2020
A clinical trans-omics multidisciplinary study to understand the role of antiretroviral therapy in premature ageing of the immune system in HIV-infection
Swedish Research Council
1 December 2018 - 30 November 2023
Unravilling the mechanisms of natural control and long term successful ART in HIV-1 infection: prospects for HIV-1 cure and vaccine development
Swedish Research Council
1 January 2018 - 31 December 2020
HIV-1 adaptation to antiretroviral therapy and its persistence in the reservoirs
Swedish Research Council
1 January 2017 - 31 December 2020
Development of a molecular surveillance phylogeographic tool to track HIV transmission networks in Bangladesh
Swedish Research Council
1 January 2016 - 31 December 2018
A translational approach to link clinical, virological and immunological findings toward a functional cure for HIV
Swedish Research Council
1 January 2013 - 31 December 2017
Optimization of HIV clinical care through bio- and healthinformatics in the global epidemic
Swedish Research Council
1 January 2013 - 31 December 2016
A randomized controlled trial to assess the effect of peer support to children with HIV in relation adherence, virological treatment failure as well as physical and cognitive development.
Swedish Research Council
1 January 2012 - 31 December 2014

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI